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mä en tienny miten pysähtyy 
nauttii hetkestä 
mieli teki omat esteensä 
 
juoksen karkuun 
tai juoksen perässä 
aistit tylsinä 
mut hampaat veressä 
 
vaikka yritin 
ei aika pysähtynyt 
viisareissa roikkumalla 
 
nyt on valkeat seinät ja 
kukat ikkunalla 
voisinpa juoksennella auringon alla 
 
 
 
-Pyhimys & Arto Tuunela: Nyt (2012) 
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ABSTRACT 
In addition to the adversities caused by the mental illness itself, individuals with 
schizophrenia have a high risk for several somatic illnesses. Moreover, mostly due to 
excess mortality from diseases and medical conditions, the life expectancy gap remains 
11 to 23 years wider in schizophrenia compared to the general population. Several 
treatment guidelines recommend regular health evaluations in schizophrenia, and state 
that general practitioners (GPs) and primary care should be the main providers of the 
somatic healthcare. Despite the extensive literature on somatic comorbidity, the big 
picture of somatic problems emerging in the suggested health examinations is not clear. 
The aim of this thesis is to elucidate the range of somatic problems and intervention 
needs among Finnish outpatients with schizophrenia. 
275 outpatients with schizophrenia underwent a structured, comprehensive health 
examination. Living conditions, medication use and lifestyle of the participants were 
inquired. In addition, severity of psychiatric problems and functional status were 
evaluated. Basic anthropometric and laboratory measurements were made. In the GP´s 
appointment, medical history was taken and a semi-structured physical examination 
conducted. Needs for lifestyle counselling and specific needs for medical intervention 
were investigated. The prevalence of metabolic syndrome, constipation and dyspepsia, 
and cerumen impaction were examined. Background variables associated with the 
aforementioned interventions and health problems were analysed. 
The participants, with mean age of 44.9 years (SD 12.6), reported the use of a mean 
of 3.3 (ranging from 0 to 13) different somatic medications. Almost half of them 
(44.9%) reported having distressing somatic symptoms on a daily basis. In the health 
examination, 81.1% of the patients received lifestyle counselling and 87.6% were in 
need of somatic interventions (i.e. additional treatment, examinations, monitoring, 
prescriptions). Obesity (OR=2.60, 95%CI 1.12-6.05, p=0.026) and smoking (OR=2.33, 
95%CI 1.06-5.13, p=0.035) were associated with a need for any type of somatic 
intervention. There was no association between medical intervention needs and GP 
visits within a year, whereas participants having visited a dentist within a year needed 
less dental intervention.  
Of the participants, 58.7% were diagnosed with metabolic syndrome. Clozapine use 
doubled the risk (OR=2.04, 95%CI 1.09-3.82, p=0.03) for metabolic syndrome whereas 
physical activity reduced the risk (OR=0.32, 95%CI 0.18-0.57, p<0.001). According to 
the definition used in the study, 31.3% of the sample had constipation and 23.6% had 
dyspepsia. Clozapine use was associated with a fivefold risk (OR=5.48, 95%CI 2.75–
10.90, p<0.001) of constipation, and paracetamol use (OR=3.07, 95%CI 1.34–7.02, 
p=0.008) and living in sheltered housing (OR=2.49, 95%CI 1.16–5.33, p=0.030) were 
also associated with an increased risk. Regarding dyspepsia, the risk was increased by 
use of non-steroidal anti-inflammatory drugs and antidiabetic medication. Cerumen 
impaction was more prevalent among the participants compared to general population 
studies. Living in sheltered housing was associated with cerumen impaction.  
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The GP identified a wide range of somatic problems leading to a multitude of 
somatic healthcare needs. Based on the findings of the current study, health 
examinations for people with schizophrenia are necessary. Individuals with 
schizophrenia usually have several risk factors for physical illness (e.g. unhealthy 
lifestyle and living conditions, medications used in the treatment). Moreover, barriers in 
getting help for somatic problems still exist.  
Obtaining information on a patient´s lifestyle and somatic medication use, medical 
history and a physical examination are all essential elements of health examinations. 
Limiting somatic health evaluations to the regulatory measurements and laboratory 
tests means that a large proportion of somatic comorbidities may remain hidden. 
Introducing and thoughtfully resourcing new procedures to the interface between 
psychiatry and general practice is vital for the recognition and improvement of the 
somatic health of individuals with schizophrenia. In particular, prevention, detection 
and treatment of obesity and smoking need to be focused on more in treatment. 
Comprehensive treatment of schizophrenia should aim to reduce the burden of 
somatic comorbidity along with the primary aim and scope of psychiatric recovery. 
This is best achieved through prevention and early recognition of physical illnesses. 
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TIIVISTELMÄ 
Skitsofreniaa sairastavilla on usein monia samanaikaisia fyysisiä sairauksia ja heidän 
odotettavissa oleva elinikänsä on muuta väestöä 11 - 23 vuotta lyhyempi. Suurin osa 
menetetyistä elinvuosista johtuu fyysisistä sairauksista. Skitsofreniaa sairastavien 
fyysisen terveyden edistämistä ja seurantaa terveystarkastuksin, sekä yleislääkäreiden ja 
perusterveydenhuollon roolia tässä tehtävässä, painotetaan hoitosuosituksissa. 
Skitsofreniaan liittyvää runsasta somaattista samanaikaissairastavuutta on tutkittu 
laajasti ja tietoa yksittäisistä sairauksista onkin runsaasti olemassa. Kokonaiskuva siitä, 
minkälaisia ja missä laajuudessa fyysisiä terveysongelmia skitsofreniaa sairastaville 
tehdyissä terveystarkastuksissa ilmenee, on kuitenkin epäselvä. Tämän tutkimuksen 
tarkoituksena on valottaa suomalaisten skitsofreniaa sairastavien avohoitopotilaiden 
fyysisiä terveystarpeita. 
Väitöstutkimuksessa yleislääkäri teki 275 skitsofreniaspektrin sairautta sairastavalle 
avohoitopotilaalle kliinisen haastattelun ja tutkimuksen sisältävän  strukturoidun, 
perinpohjaisen terveystarkastuksen. Tarkastuksessa selvitettiin potilaiden elinoloja ja 
elintapoja, lääkkeiden käyttöä, toimintakykyä sekä fyysisiä ja psyykkisiä oireita. 
Potilaille tehtiin perusmittauksia ja heistä otettiin laboratoriokokeita. 
Elämäntapaohjauksen ja jatkointerventioiden (tutkimukset, seurannat, hoidolliset 
toimenpiteet) tarve määriteltiin, sekä selvitettiin taustamuuttujien yhteyttä 
jatkointerventioihin. Lisäksi tutkittiin metabolisen oireyhtymän, ummetuksen ja 
ylävatsaoireiden sekä korvan vahatulpan esiintyvyyttä ja taustatekijöitä. 
Tutkimukseen osallistuneiden keski-ikä oli 44.9 (SD 12.6) vuotta. Heillä oli 
käytössä keskimäärin 3.3 (vaihteluväli 0 - 13) erilaista somaattista lääkitystä. 
Tutkituista lähes puolet (44.9%) raportoi päivittäin haittaavia fyysisiä oireita. 81.1% 
osallistuneista sai elämäntapaneuvontaa ja 87.6% oli jonkinlaisen jatkohoidon, 
seurannan tai tutkimuksen tarpeessa. Yleisesti interventiontarpeita ennustivat lihavuus 
(OR=2.60, 95%CI 1.12-6.05, p=0.026) ja tupakointi (OR=2.33, 95%CI 1.06-5.13, 
p=0.035). Yleislääkärikäynti vuoden sisällä ei vähentänyt tarvetta fyysisen terveyden 
interventioihin, mutta hammaslääkärikäynti vuoden sisällä vähensi suun sairauksien 
interventioiden tarvetta.  
Metabolinen oireyhtymä diagnosoitiin 58.7% tutkimukseen osallistuneista. 
Klotsapiinin käyttö kaksinkertaisti  (OR=2.04, 95%CI 1.09-3.82, p=0.03) metabolisen 
oireyhtymän riskin ja fyysinen aktiivisuus vastaavasti vähensi riskiä alle puoleen 
(OR=0.32, 95%CI 0.18-0.57, p<0.001). Tutkimuksessa käytetyn määritelmän 
mukaisesti osallistuneista 31.3% oli ummetusta ja 23.6% ylävatsavaivoja. Klotsapiinin 
käyttö oli yhteydessä yli  viisinkertaiseen ummetusriskiin (OR=5.48, 95%CI 2.75–
10.90, p<0.001), myös parasetamolin käyttö (OR=3.07, 95%CI 1.34–7.02, p=0.008)   ja 
tuettu asuminen (OR=2.49, 95%CI 1.16–5.33, p=0.030) lisäsivät ummetusriskiä. 
Ylävatsavaivojen esiintymistä ennustivat tulehduskipu- ja diabeteslääkkeiden käyttö. 
Korvakäytävän tukkiva vahatulppa oli tutkituilla selkeästi yleisempi kuin kirjallisuuden 
mukaan yleisväestössä. Tuettu asuminen ennusti suurentunutta riskiä korvan 
vahatulppaan.  
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Yleislääkäri havaitsi terveystarkastuksissa skitsofreniapotilailla runsaasti fyysisiä 
ongelmia ja niistä juontuvaa seurannan ja hoidon tarvetta. Tämän tutkimuksen 
perusteella säännöllisten terveystarkastusten tekeminen skitsofreniaa sairastaville on 
mielekästä ja tarpeellista. Skitsofreniaa sairastavilla on usein psyykkisen sairauden 
oireisiin, elintapoihin ja asumisolosuhteisiin, psykiatrisiin lääkityksiin sekä 
hoitojärjestelmään liittyviä haasteita, jotka voivat johtaa hankaloituneeseen avun 
saamiseen ruumiillisiin sairauksiin. 
Terveystarkastuksissa skitsofreniapotilaiden elintavat, lääkitysten käyttö sekä 
fyysinen oireilu on tärkeää selvittää. Potilaille tulee myös tehdä kliininen tutkimus 
perusmittausten (painoindeksi, vyötärön ympärys, verenpaine) ja 
laboratoriotutkimusten ohella, muuten moninaiset terveysongelmat voivat jäädä 
havaitsematta. Runsas somaattinen oireilu ja hoidontarve, sekä terveydelle haitallisten 
elintapojen yleisyys on huomioitava resurssien suuntaamisessa skitsofreniaa 
sairastavien fyysisen terveyden hoitoon. Uudentyyppisten toimintamallien kehittäminen 
psykiatrian ja yleislääketieteen rajapintaan on tärkeää skitsofreniaa sairastavien 
terveyden edistämiseksi. Erityisesti lihavuuden ja tupakoinnin ennaltaehkäisyyn, 
seurantaan ja hoitoon on panostettava aiempaa enemmän. 
Kokonaisvaltainen skitsofrenian hoito tähtää ensisijaisen tavoitteensa, psyykkisen 
toipumisen ja oireiden hallinnan, ohella myös fyysisen sairauskuorman vähentämiseen. 
Parhaiten fyysistä terveyttä vaalitaan kun sairauksia pyritään ennaltaehkäisemään ja 
kun ne todetaan oikea-aikaisesti. 
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1 INTRODUCTION 
Physical and psychological well-being are tightly intertwined. Besides carrying, in 
most cases, the extra burden of comorbid somatic diseases during their lifetime, a 
person diagnosed with schizophrenia is likely to die 11-23 years prematurely 
(Nordentoft et al., 2013,Tiihonen et al., 2009). Increased mortality in schizophrenia 
is mainly due to mortality from somatic diseases and medical conditions such as 
cardiovascular, malignant and respiratory diseases (Crump et al., 2013). The 
underlying causes for the myriad of somatic illnesses in schizophrenia are numerous, 
spanning from the genetic structure of an individual to the influences of the 
environment, unhealthy lifestyle, medication side effects, socioeconomic 
disadvantages, and the impact of the psychiatric illness itself, such as negative and 
cognitive symptoms, or difficulties in self-care and communication. Moreover, 
service-related factors, e.g. lack of resources and integration of psychiatric and 
somatic healthcare, may endanger individuals with schizophrenia from getting 
adequate treatment for their somatic problems (De Hert et al., 2011a). 
Abundant literature and guidelines exist stressing the importance of monitoring 
physical health in schizophrenia. However, the range of somatic conditions needing 
medical treatment or further investigation that may emerge in a health examination 
has rarely been investigated. Research on comorbid diseases in schizophrenia is 
often based on the data derived from registers or health records. Therefore only the 
diagnosed diseases are taken into account. In studies based on registers, the data on 
lifestyle and other relevant background variables influencing somatic health is often 
limited. On the other hand, clinical studies usually focus on a single disease at a 
time.  
In the healthcare system, general practitioners (GPs) are usually the providers of 
overall physical health services. What should a GP expect when a person with 
schizophrenia comes to visit for the recommended health examination? The expected 
somatic healthcare needs ought to be known in order to design services concerning 
prevention and treatment of somatic illnesses for patients with schizophrenia. 
Because of the knowledge gap in somatic comorbidity among patients with 
schizophrenia living in sheltered housing, the impact of living conditions on physical 
health is of specific interest. 
This thesis aims to assess comorbidities and risk factors associated with 
metabolic syndrome, gastrointestinal symptoms and cerumen impaction, and 
physical healthcare needs in general, by somatic health examinations among 
outpatients with schizophrenia.  
In the study, the GP performed a comprehensive health examination of 275 
outpatients with schizophrenia spectrum disorders. The structured examination 
consisted of a review of medical records, visit to a nurse, basic laboratory tests and 
measurements, assessment of the medical history and physical examination of the 
patient by the GP.  
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2 REVIEW OF THE LITERATURE 
2.1 SCHIZOPHRENIA 
Schizophrenia is a severe and often substantially disabling mental disorder which 
emerges in most cases in young adulthood. Schizophrenia usually causes several 
challenges for both the affected person and their close ones, and is one of the most 
expensive diseases to society. Core symptoms of schizophrenia constitute psychotic, 
i.e. positive (hallucinations, delusions), negative (lack of drive and volition, 
withdrawal from social interaction), disorganized (positive thought disorder, bizarre 
behaviour) and cognitive (disturbances in attention, memory, executive functioning) 
symptoms. Dopamine dysregulation in the brain is thought to be responsible for 
psychotic symptoms (Howes and Murray, 2014). Affective symptoms (depression 
and mania) are less pronounced in schizophrenia compared to affective psychoses 
(bipolar disease and psychotic depression) (van Os and Kapur, 2009).  
The aetiology of schizophrenia is heterogeneous. The heritability of 
schizophrenia is high, 65-80 per cent, but environmental risk factors also have an 
important role in the aetiology (Owen et al., 2016). The genetic background of 
schizophrenia is polygenic, but rare high-risk genetic variants also exist (Owen et al., 
2016). It has been suggested that genetic vulnerability, pre- and perinatal hazards to 
the brain and adverse life events in early childhood together cause altered 
neurodevelopment and sensitize the dopamine system in the brain (Howes and 
Murray, 2014). The forthcoming adversities in childhood and adolescence (such as 
maltreatment and abuse, bullying, discrimination), combined with the underlying 
susceptibility to increased dopamine release, are thought to cause a bias to 
interpretation of experiences of stressful situations and lead to psychotic 
interpretations of neutral incidents (Howes and Murray, 2014,Hietala et al., 2015). 
Individuals with schizophrenia spectrum disorders have a 2.5 to 3.5-fold higher 
mortality risk compared to the general population, mainly attributable to death from 
somatic diseases (Saha et al., 2007,Lumme et al., 2016). Strikingly, a threefold 
mortality rate compared to the control population due to mortality from diseases and 
medical conditions was shown to occur already within the first five years after the 
onset of schizophrenia in a Finnish register study (Kiviniemi et al., 2010).  
The lifetime prevalence of schizophrenia in Finland was 1% in the Psychoses in 
Finland (PIF) Study (Perälä et al., 2007). PIF was based on a large general 
population health examination study, the Health 2000 Study, and the study sample 
was representative of the Finnish population aged 30 years and over. Recently, 
Danish researchers estimated in a register-based follow-up study of the Danish 
population that 1.93% of men and 1.56% of women in the population develop 
schizophrenia during their lifetime (Pedersen et al., 2014).  
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The International Statistical Classification of Diseases and Related Health 
Problems, 10th revision (ICD-10) by the World Health Organization (WHO) is 
currently used in clinical practice to diagnose psychiatric disorders in Finland. ICD-
10 groups schizotypal disorder, delusional disorders, acute and transient psychotic 
disorders, schizoaffective disorder, other non-organic psychotic disorders and 
unspecified non-organic psychosis into the same group of disorders with 
schizophrenia, F20-29 (WHO World Health Organization, 1992). The most 
prevalent disorders of the aforementioned, after schizophrenia, are schizoaffective 
disorder and unspecified non-organic psychotic disorders (Perälä et al., 2007). The 
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)  
(American Psychiatric Association, 2013) is the psychiatric classification system 
used in the US and widely in the research. Tables 1 and 2 show the diagnostic 
criteria of schizophrenia and schizoaffective disorder according to ICD-10 and 
DSM-5 classifications. 
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Table 1. Diagnostic criteria of schizophrenia according to ICD-10 and DSM-5. 
 
ICD-10 
 
 
A) At least one of the following: echoing/insertion/withdrawal/ broadcasting 
of thought, delusional perceptions, hallucinatory voices, impossible 
delusions of some kind 
or  
B) At least two of the following: persistent hallucinations in any modality, 
incoherence or irrelevant speech, catatonic behaviour, negative symptoms  
C) Present for most of the time for at least 1 month  
D) Disorder is not caused by substance use or organic brain disease 
 
 
DSM-5 
 
 
A) At least two of the following (at least one must be 1, 2 or 3) for at least 1 
month: 1.Delusions, 2. Hallucinations, 3. Disorganized speech, 4. Grossly 
disorganized or catatonic behaviour, 5. Negative symptoms  
B) Level of functioning has to be significantly and long term lowered 
compared to the previously achieved level  
 
C) Continuous signs of the disturbance persist for at least 6 months, must 
include criterion A symptoms for at least 1 month  
D) Schizoaffective disorder and depressive or bipolar disorder with 
psychotic symptoms ruled out 
 
E) The disturbance is not caused by substance use or medical conditions  
F) If a patient has a history of autism spectrum or communication disorders 
from childhood, schizophrenia diagnosis can be made in case of prominent 
delusions/ hallucinations and other required symptoms of schizophrenia 
are present for at least 1 month 
 
ICD-10, The International Statistical Classification of Diseases and Related Health Problems, 
10th revision   
DSM-5, The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
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Table 2. Diagnostic criteria of schizoaffective disorder according to ICD-10 and DSM-5. 
 
 
ICD-10 
 
 
A) Psychotic symptoms of schizophrenia (except for negative and 
persistent hallucinatory symptoms) present for most of the time during a 
period of at least two weeks  
B) Manic or at least moderately severe depressive episode and psychotic 
symptoms must be present within same episode of the disorder and 
simultaneously for at least some time of it  
C) Disorder is not caused by substance use or organic brain disease 
 
 
 
DSM-5 
 
 
A) A concurrent period of illness with major mood episode (major 
depressive or manic) and criterion A symptoms of schizophrenia  
 
B) Delusions or hallucinations for at least 2 weeks in the absence of a 
major mood episode, during the lifetime duration of the illness  
 
C) Major mood episode symptoms present for the majority of the duration 
of the illness 
 
D) The disturbance is not caused by substance use or medical conditions 
 
 
ICD-10, The International Statistical Classification of Diseases and Related Health Problems, 
10th revision   
DSM-5, The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
 
 
Since the 1950s and the discovery of chlorpromazine, antipsychotic (AP) medication 
has been the cornerstone of schizophrenia treatment. The principal mechanism of AP 
drugs is to block dopamine 2 receptors in the brain to consequently reduce psychotic 
symptoms. However, APs have very limited effectiveness in treating negative and 
cognitive symptoms. First-generation antipsychotics (FGA) have quite an exclusive 
affinity for dopamine 2 receptors, often leading to drug-induced movement 
disorders, i.e. extrapyramidal symptoms. Second-generation antipsychotics (SGA) 
have a wider receptor binding profile (including serotonergic, α adrenergic, 
histaminergic, muscarinic receptors) compared to FGA, and thus somewhat different 
side effect profiles (Correll and Kane, 2014a). Most SGA are prone to cause 
metabolic side effects such as weight gain, dyslipidemia or impaired glucose 
tolerance. Nevertheless, both FGA and SGA may cause metabolic side effects and 
extrapyramidal symptoms. In Finland, SGA have replaced FGA as primary drug 
therapy for schizophrenia in clinical practice (The Finnish Medical Society 
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Duodecim and the Finnish Psychiatric Association, 2015). To date, clozapine, which 
is classified as a SGA, is considered the most effective AP compound, but due to 
clozapine-associated agranulocytosis risk, it is reserved for patients who have not 
responded to two other APs (Leucht et al., 2013). 
In addition to AP medication, treatment options for schizophrenia include 
psychosocial treatments (e.g. psychotherapy, family interventions, occupational and 
cognitive rehabilitation), treatments for comorbid psychiatric problems (e.g. 
depression, substance use), somatic follow-ups and counselling for a healthy lifestyle 
(National Institute for Health and Care Excellence, 2014,The Finnish Medical 
Society Duodecim and the Finnish Psychiatric Association, 2015). In Finland, 
schizophrenia is suggested to be treated mainly in specialized psychiatric outpatient 
care, while somatic treatment of outpatients should be taken care of in primary care 
(The Finnish Medical Society Duodecim and the Finnish Psychiatric Association, 
2015). Of utmost importance in the treatment of schizophrenia is a long-term, 
confidential relationship between the patient and the mental healthcare provider, 
while also taking carers’ and other family members’ perspective (if any) into 
account. Having a clear plan in the treatment, knowing how to react in the possible 
relapse phase, supporting patient´s treatment adherence and somatic well-being, as 
well as integration into society are essential elements in the treatment of 
schizophrenia (The Finnish Medical Society Duodecim and the Finnish Psychiatric 
Association, 2015). 
2.2 SOMATIC COMORBIDITY IN SCHIZOPHRENIA 
Individuals with schizophrenia have a high risk for a wide range of somatic illnesses 
(Smith et al., 2013,Leucht et al., 2007). In this chapter an overview of them will be 
presented.  
Despite the extensive amount of literature published on somatic comorbidity in 
schizophrenia, to the author’s knowledge, the most recent studies using the method 
of a structured, comprehensive physical examination by a physician in a clinical 
outpatient setting reporting summarized findings of the physical health problems 
date back to the 1980s. Table 3 presents four such health examination studies. 
During that period the risk of failing to diagnose somatic illnesses by labelling 
patients’ symptoms as “psychosomatic” raised concerns (Koranyi, 1979). On the 
other hand, the possible impact of somatic problems aggravating patients´ 
psychiatric state seems to have been of special interest. Regarding the latter aspect, 
the authors shared a point of view that somatic comorbidities found in their studies 
represented mostly common physical conditions treated by GPs in primary care, 
instead of “mimics”, i.e. somatic conditions judged as psychiatric illness (Barnes et 
al., 1983,Maricle et al., 1987,Honig et al., 1989). Conflictingly, in an earlier study, 
one half of the patients were estimated as having had a major somatic illness that 
aggravated their mental condition (Koranyi, 1979). 
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Table 3. Examples of historical studies of structured health examinations in outpatients with 
schizophrenia. 
Author 
Country 
Sample Method of 
somatic 
examination 
Definition of 
the somatic 
disease 
Results 
(Koranyi, 
1979) 
 
Canada 
 
 
Clinical data from 
consecutive new 
patients in the 
university 
psychiatric clinic 
over 7 years 
 
2090 patients: 
547 psychotic 
illness 
Routine 
evaluation 
comprising a 
“complete 
physical 
examination” 
and laboratory 
tests 
 
Further 
examination 
when needed 
Major physical 
illness: “a 
condition that 
causes active 
symptoms and 
concern on 
medical 
grounds, and 
requires medical 
treatment” 
44% men, mean 
age 33 years (men) 
and 34 years 
(women) 
 
43% had a major 
physical illness, 
almost half 
undiagnosed  
 
Most common 
diagnostic 
categories: 
circlulatory, 
neurological, 
endocrine, digestive 
system 
(Barnes et 
al., 1983) 
 
US 
 
 
Convenience 
sample of chronic 
mental hygiene 
clinic patients with 
no physical 
examination within 
1 year 
 
147 patients: 
26 schizophrenia 
Nurse 
practitioner: 
stuctured 
interview of 
certain 
symptoms, 
physical 
examination, 
laboratory tests, 
chest x-ray 
 
Abnormal 
findings led to a 
consultation with 
treating 
psychiatrist and 
internist 
Medical illness: 
abnormality in 
the screening 
needing   
referral to 
further 
evaluation or 
treatment 
Mean age 52 years, 
95% men 
 
34% were referred  
 
26% had medical 
illnesses, 13% 
previously 
undiagnosed, 13% 
received a new 
treatment. Most 
common diagnoses: 
hypertension, 
diabetes, chronic 
pulmonary disease, 
inguinal hernia 
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(Maricle et 
al., 1987)  
 
US 
 
Randomly selected 
sample from 100 
community mental 
health clinic 
patients 
 
43 patients,  
24 with 
schizophrenia 
Questionnaire, 
physical 
examination, 
Mini Mental 
State 
Examination, 
laboratory tests 
Medical 
diagnosis: a 
combination of 
all relevant 
information 
gathered in the 
examination 
Mean age 43 years, 
63% men 
 
88% had physical 
symptoms 
 
88% had any 
medical diagnosis, 
49% had at least 
one new condition 
needing further 
medical attention, 
most often regarding 
hyperlipidaemia, 
diabetes, 
hypertension, vision/ 
hearing problems 
(Honig et al., 
1989)  
 
Netherlands 
 
All consenting 218 
patients from a 
psychiatric 
outpatient clinic 
 
156 patients,  
48 with psychotic 
disorder 
Specialist in 
internal 
medicine:  
medical history, 
physical 
examination, 
laboratory tests  
 
 
Physical 
disease: 
“manifestation 
needing medical 
treatment or 
further 
investigation” 
Mean age 46 years, 
36% men 
 
88% had physical 
complaints 
 
53% had at least 
one certain or 
probable somatic 
disease, most often 
hypertension, 
gastroenterological, 
endocrine and 
musculoskeletal 
problems 
2.2.1 OBESITY   
Obesity in adults is defined as body mass index (BMI) ≥30 kg/m2. Obesity is a risk 
factor for a multitude of diseases and is associated with increased mortality risk and 
difficulties in physical activity. After established, obesity is difficult to overcome 
due to biological adaptations it causes in the body (Ochner et al., 2015). Globally,  
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the prevalence of obesity has more than doubled since the 1980s, and the worldwide 
prevalence of obesity in 2014 was 15% in females and 11% in males (WHO World 
Health Organization, 2016a). In Finland, one fifth of the adult population is obese 
(Borodulin et al., 2015).  
Obesogenic environments promote the obesity pandemic, especially by excessive 
energy supply and over-consumption (Swinburn et al., 2011). Psychiatric inpatient 
facilities represent a unique form of obesogenic environment (Faulkner et al., 2009). 
As an example, patients may have limited access to leave the ward to go for a walk 
because of safety issues, while the available food may contain excessive amounts of 
energy.  
Among patients with schizophrenia, obesity is approximately twice as prevalent 
as in the general population (Allison et al., 2009). The metabolically most hazardous 
form of obesity, central obesity, is especially common (Saarni et al., 2009). Risk 
factors for obesity in patients with schizophrenia are psychotropic medications, 
unhealthy diet and sedentary lifestyle (Manu et al., 2015). Table 4 shows the 
propensity of commonly used AP medications in Finland to cause weight gain. AP 
medications have been shown to increase appetite and delay satiety signalling due to 
serotonin 5-HT2C and histamine H1 receptor antagonism, leading to increased food 
intake (Correll et al., 2015). In addition, dopamine receptor antagonism and effects 
on several neurotransmitters and gut hormones involved in appetite control 
participate in AP-induced weight gain (Manu et al., 2015,Siskind et al., 2016). APs 
may also decrease resting energy expenditure (Manu et al., 2015). Moreover, there is 
preliminary evidence for elevated risk related to some receptor genes predisposing to 
AP-induced weight gain (Shams and Muller, 2014).  
Risk for weight gain is especially pronounced among patients exposed to AP 
compounds for the first time, and it occurs within weeks after the initiation of the 
treatment (Tarricone et al., 2010). In a recent Finnish follow-up study on patients 
with first-episode psychosis (FEP), 81.8% of the sample increased more than 7% of 
their weight within 12 months (Keinänen et al., 2015).  
 
Table 4. Top 5 antipsychotics used in Finland in 2014 (Finnish Statistics on Medicines 2015) and 
their propensity to cause weight gain according to Leucht et al., 2013. 
 
 
 
Defined Daily Dose/ 
1000 inhabitants/day 
 
Weight gain compared to 
placebo 
Olanzapine 5.96 +++ 
Quetiapine 5.30 ++ 
Clozapine 2.34 +++ 
Risperidone 2.33 ++ 
Aripiprazole 1.81 + 
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Weight gain and abdominal obesity have been shown to be associated with 
psychological distress and lower self-esteem among patients with schizophrenia (De 
Hert et al., 2006,Al-Halabi et al., 2012). Another FEP study on treatment adherence 
showed that patients who were concerned of being overweight due to use of 
psychiatric medication were prone to lower the dosages of the medication by 
themselves (Wong et al., 2011). 
Obesity has been shown to associate with difficulties in moving and performing 
daily activities in the general population (Alley and Chang, 2007). Vancampfort et 
al. studied functional exercise capacity in 60 patients with schizophrenia and 40 
healthy controls by a 6 minute walk test. The patients had significantly higher BMI 
and a shorter mean walking distance compared to healthy controls. Moreover, higher 
BMI and lack of reported leisure time physical activity were associated with reduced 
walking distance and lower physical health-related quality of life among patients 
(Vancampfort et al., 2011a).  
In addition, high BMI was recently associated with more frequent psychiatric 
hospital readmissions in a retrospective study of 945 psychiatric patients (35.8% 
with a diagnosis of schizophrenia or psychotic disorder not otherwise specified) in 
the US (Manu et al., 2014b). The authors speculated that the association might be 
due to obese patients´ poorer adherence to psychotropic medications, or to the 
alterations in the inflammatory status caused by overweight that might exacerbate 
psychiatric symptoms (Manu et al., 2014b). Interestingly, this finding conflicts older 
reports linking weight gain or higher BMI with better psychiatric treatment 
outcomes in schizophrenia (Meltzer et al., 2003,Salokangas et al., 2007). 
2.2.2 METABOLIC SYNDROME  
Metabolic syndrome (MetS) is a proinflammatory and a prothrombotic state of the 
body consisting of abdominal obesity, hyperglycaemia, elevated blood pressure and 
dyslipidemia (Alberti et al., 2005, Grundy et al., 2005). Risk for type 2 diabetes 
(T2D), cardiovascular (CV) diseases and overall mortality is elevated in individuals 
with MetS (Lakka et al., 2002, Pajunen et al., 2010). Definitions by the International 
Diabetes Federation (IDF) and American Heart Association/National Heart, Lung 
and Blood Institute (AHA/NHLBI) are currently used to diagnose MetS. These 
definitions differ in two ways: IDF has an 8cm lower cut-off for waist circumference 
and requires abdominal obesity to be present, compared to the AHA/NHLBI criteria 
(Table 5). 
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Table 5. AHA/NHLBI and IDF criteria for metabolic syndrome. 
 AHA/NHLBI 
3 of 5 required 
IDF 
waist plus 2 required  
Waist circumference 
(cm) 
≥102 in men, ≥88 in women ≥94 in men, ≥ 80 in women* 
Blood pressure  
(mmHg) 
≥130/ 85  
or antihypertensive drug 
treatment 
≥130/ 85  
or antihypertensive drug 
treatment 
Fasting glucose (mmol/l) ≥5.6  
or drug treatment for 
elevated glucose 
≥5.6  
or drug treatment for elevated 
glucose 
HDL cholesterol (mmol/l) ≥1.03 in men, ≥1.3 in women 
or drug treatment for 
reduced HDL  
 
≥1.03 in men, ≥1.3 in women 
or drug treatment for reduced 
HDL  
 
Triglycerides (mmol/l) ≥1.7  
or drug treatment for 
elevated triglycerides 
≥1.7  
or drug treatment for elevated 
triglycerides  
 
 
* If BMI is >30, central obesity can be assumed without measuring the waist circumference 
 
AHA/NHLBI, American Heart Association/National Heart, Lung and Blood Institute; IDF, 
International Diabetes Federation; HDL, High-Density Lipoprotein; BMI, Body Mass Index 
 
MetS and cardiometabolic risk have been intensively studied and discussed in 
psychiatric literature during the past 15 years, since the era of wide use of SGA 
began (Meyer, Stahl, 2009). According to a meta-analysis of almost 25 000 patients, 
the prevalence of MetS in schizophrenia is 32.5%, and among clozapine users it rises 
to 51.9%, whereas in the general population the age-adjusted prevalence of MetS in 
Europe is 18.4% for men and 14.4% for women (Mitchell et al., 2013). Higher rates 
of MetS have been reported recently: the Australian National Survey of Psychosis 
reported that 60.8% of the participants with psychotic illnesses suffered from MetS 
(Morgan et al., 2014) and IMPaCT, a large British outpatient study of individuals 
with psychotic illnesses, suggested a prevalence of 56.8% for MetS (Gardner-Sood 
et al., 2015).  
The prevalence of MetS increases with age, which also explains differences in 
MetS prevalence across various studies. In the PIF Study there was no difference in 
the prevalence of MetS between patients aged ≥55 years with a diagnosis of 
psychotic disorder and a control group of respective age, whereas the younger age 
group (30-54 years) of individuals with schizoaffective disorder, delusional disorder 
or psychotic disorder not otherwise specified, had a MetS prevalence of 47.2% 
compared with 22.1% in the general population of the same age (Suvisaari et al. 
2007). Notably in the PIF Study, only a minority of the schizophrenia group used 
SGA and the mean age of the studied population was 53 years. In the older cohort 
there was no difference observed in MetS prevalence, presumably because the 
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prevalence of MetS increases with age, but possibly also due to a “healthy survivor” 
effect in people with psychotic disorder. Another Finnish study, the Northern 
Finland 1966 birth cohort, demonstrated a fourfold prevalence rate of MetS in 
schizophrenia compared to persons without psychiatric diagnoses at age 31 years 
(Saari et al., 2005). Together, these results suggest that the risk of MetS in people 
with psychotic disorders compared to the general population is highest in young 
individuals, and the risk difference decreases with increasing age. Nevertheless, 
most components of Mets have been shown to be more prevalent among persons 
with psychotic illnesses throughout life (from 25 to 65 years) compared to those of 
the general population (Foley et al., 2013).  
Unhealthy lifestyle, AP medications and possibly also genetic factors are 
predictors of MetS in schizophrenia (Mitchell et al., 2013, Malan-Muller et al., 
2016). According to a meta-analysis on first-episode and unmedicated schizophrenia 
patients, the prevalence of MetS was only 9.9% and 9.8%, respectively, indicating 
that antipsychotic medications have an important role in the development of MetS 
(Mitchell et al., 2013). The most recent review assessing MetS among patients with a 
severe mental illness (SMI) showed that the prevalence of MetS associated with the 
use of APs varied notably: from 47% (clozapine) to 37% (quetiapine), 36% 
(olanzapine), 28% (FGA) and 19% (aripiprazole) (Vancampfort et al., 2015a). 
However, the rates are not entirely comparable since these rates are not adjusted for, 
e.g. age or previous exposure to other antipsychotics. 
2.2.3 DIABETES  
Diabetes is classified as two main types, type 1 and type 2 (T2D), although there are 
other rare forms like latent autoimmune diabetes of adults and maturity onset 
diabetes of the young. In Finland, the age-standardized prevalence for diabetes was 
6.7% in 2014 according to WHO global status report on non-communicable diseases 
(WHO World Health Organization, 2014b). Of the patients with diabetes in Finland, 
75% have T2D, an illness characterized by insulin resistance and, usually in the later 
stages, insufficient insulin release from pancreatic beta cells. Type 1 diabetes is an 
autoimmune disease where the beta cells responsible for insulin secretion are 
destroyed and permanent insulin replacement is needed from the beginning of the 
disease (The Finnish Medical Society Duodecim, the Finnish Society of Internal 
Medicine and the Medical Advisory Board of the Finnish Diabetes Society, 2016).  
Classic symptoms of diabetes are thirst, unintentional weight loss and excessive 
urination. Diabetes diagnosis is made in an asymptomatic person when in two 
separate measurements fasting plasma glucose is ≥7.0mmol/l, or >11mmol/l at the 2-
hour time point in an oral glucose tolerance test, or once measured HbA1c is 
≥48mmol/mol (≥6.5%). In addition, an occult glucose measurement >11mmol/l from 
a person with classical symptoms suffices for diagnosing diabetes (The Finnish 
Medical Society Duodecim, the Finnish Society of Internal Medicine and the 
Medical Advisory Board of the Finnish Diabetes Society, 2016). A precursor of 
T2D, impaired fasting glucose, is considered when fasting plasma glucose is 
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between 6.1-6.9mmol/l (according to WHO) or between 5.6-6.9mmol/l (according to 
American Diabetes Association).  
T2D is a well-known risk factor for mortality, CV diseases, kidney failure, limb 
amputations and blindness (WHO World Health Organization, 2016b). Furthermore, 
among patients over 50 years old diabetes associates with disabilities affecting many 
aspects of life (physical performance, daily living, social participation) (Tyrovolas et 
al., 2015). Among patients with schizophrenia, T2D may be even a stronger risk 
factor for mortality compared to the non-schizophrenic population (Schoepf et al., 
2012). In the 9-year register-based follow-up of the PIF sample, a 3-fold mortality 
risk in the schizophrenia group was found compared to the general population, 
baseline T2D predicting increased mortality risk along with smoking and advanced 
age (Suvisaari et al., 2013). 
Individuals with schizophrenia have a 2 to 5-fold risk for T2D compared to the 
general population (Ward and Druss, 2015a). In the PIF Study, patients with 
schizophrenia had an almost 5-fold risk of T2D compared to the general population 
(Suvisaari et al., 2008). In a large meta-analysis of 145 718 patients and almost 4 
500 000 controls, the prevalence of T2D in schizophrenia was 9.5% in the whole 
sample, and 10.8% when T2D diagnosis was based on diagnostic criteria instead of 
medical records or patient self-report (Stubbs et al., 2015c). The risk for T2D in 
schizophrenia was 2.5-fold in studies using diagnostic criteria, and just like in the 
general population, increasing age was an important moderator for T2D risk (Stubbs 
et al., 2015c). In a meta-analysis of adolescents exposed to AP treatment with a 
mean age of 14, AP users had a higher risk for T2D compared with healthy 
adolescents and also a higher risk compared to adolescents with psychiatric disorders 
who were not using APs (Galling et al., 2016). However, disturbances in glucose 
metabolism in the onset of schizophrenia were recently established in a large meta-
analysis assessing AP-naïve first-episode schizophrenia patients (Pillinger et al., 
2017). Accordingly, it has been suggested that schizophrenia and T2D might even 
share some aetiological mechanisms, but causality has not been proven (Perry et al., 
2016). The link between type 1 diabetes and schizophrenia remains unclear. Some 
studies have found an increased risk of type 1 diabetes among patients with 
schizophrenia (Benros et al., 2014), whereas others have suggested a decreased risk 
of schizophrenia among patients with type 1 diabetes (Juvonen et al., 2007). 
Effects of AP medications on risk of T2D are mediated both by weight gain and 
obesity, but also irrespective of them (probably due to muscarinic M3 receptor 
blockage influencing insulin secretion) by dysregulation of glucose homeostasis and 
subsequent insulin resistance (Correll et al., 2015). Other, universal risk factors are 
family history of T2D, obesity, lack of physical activity, poor diet, smoking, and low 
socioeconomic status (Suvisaari et al., 2016).  
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2.2.4 CARDIOVASCULAR DISEASES 
Of CV diseases, ischaemic heart disease and stroke are the leading causes of death 
worldwide (WHO World Health Organization, 2017b). Meta-analyses have shown 
increased risk for coronary and congestive heart diseases and stroke in schizophrenia 
(Fan et al., 2013,Li et al., 2014). According to a Nordic 13-year follow-up study, the 
risk for CV death in Finland was 2.5-fold higher for patients with schizophrenia 
compared to the general population (Laursen et al., 2013). A recent study from 
Sweden, examining time trends in mortality between 1987 and 2010 among people 
with SMI, showed that in schizophrenia, CV morbidity and mortality gaps remained 
wide compared to the general population throughout the study period (Ösby et al., 
2016).  
There is contradictory evidence on the association between schizophrenia and the 
most prevalent CV disease at population level, hypertension. Some studies have 
shown a slightly higher risk of hypertension (Bresee et al., 2010) compared to 
controls, whereas some suggest a lower risk of hypertension (Suvisaari et al., 2007). 
In the former study the data was extracted from a national health administrative 
database, and in the latter from blood pressure measurements in health examinations 
of a nationally representative sample. Differences in the prevalence of hypertension 
in the general population in different countries may contribute to these contradictory 
results (Wolf-Maier et al., 2003). 
There are certain phenomena to consider when assessing hypertension in persons 
with schizophrenia. Vasodilatation caused by α adrenergic blockage of AP 
medications lowers the blood pressure (Buckley and Sanders, 2000). In addition, 
beta-blockers may be classified as treatment for hypertension although the real 
indication for beta-blockers has been treatment of AP-induced tachycardia instead, 
especially in patients using clozapine (Nielsen et al., 2013). Beta-blockers lower 
blood pressure regardless of indication. Thus, a patient may use typical 
antihypertensive medication without hypertension, and possibly after discontinuing 
the blood pressure lowering AP medication, he or she may develop hypertension. In 
addition, a diagnosis of blood pressure should be based on several measurements 
(The Finnish Medical Society Duodecim and the Finnish Hypertension Society, 
2014). It may be difficult to carry out such a follow-up if a person has cognitive 
deficits or cannot afford a personal measurement device. These difficulties may lead 
to misdiagnosing hypertension in individuals with schizophrenia. 
Risk for sudden cardiac death is increased in schizophrenia and may be mediated, 
in addition to coronary disease, by changes in autonomic regulation of heart (typical 
for schizophrenia) and arrhythmias. Inherited long QT syndrome may lead to even 
higher risk for AP-induced QT prolongation and fatal arrhythmias (Koponen et al., 
2008). 
According to a review, CV risk in terms of lipid and glucose abnormalities and 
obesity is equal for persons at the onset of a psychotic illness compared to healthy 
controls, but the risk factors start to accumulate soon after the initiation of the 
psychiatric treatment (Foley and Morley, 2011). Regarding CV risk, a large FEP 
study on young adults in their twenties with a mean 1.5-month exposure to APs 
showed an association between duration of AP medication and development of lipid 
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abnormalities (increased low-density lipoproteins and triglycerides, decreased high-
density lipoproteins) (Correll et al., 2014b). Concerning the mechanisms of drug-
induced lipid abnormalities, APs have also been shown to directly influence the 
biosynthesis of fatty acids and cholesterol (Foley and Mackinnon, 2014). 
Patients using AP medication (SGA users more often than FGA users) had a 
higher risk for deep venous thrombosis and pulmonary embolism compared to their 
matched controls in a British primary care database study, and the researchers 
estimated that a schizophrenia diagnosis would account for an increased risk for 
thrombosis similar to cancer, oral contraceptive use and hip fracture (Parker et al., 
2010). Clozapine use seems to a bear higher risk for pulmonary embolism compared 
to other APs (Allenet et al., 2012). Possible medication-specific mechanisms in AP-
treated patients are sedation, obesity, hypotension, antiphospholipid antibodies, 
increased platelet activation and hyperprolactinemia, along with common risk factors 
like immobilization, severe infections and malignant illnesses (Masopust et al., 
2012). There is also some evidence that patients with schizophrenia may have 
abnormalities in overall coagulation, which may contribute to their increased risk of 
venous thromboembolism (Chow et al., 2015). 
Moreover, there is evidence of increased rates of congestive heart failure, 
cerebrovascular and peripheral vascular diseases (Laursen et al., 2011) and chronic 
thromboembolic pulmonary hypertension in schizophrenia (Suzuki et al., 2016). 
Dysregulated autonomic functions (heart rate, blood pressure, breathing) have 
been established in unmedicated patients with schizophrenia, and these alterations 
are shown to correlate with psychiatric symptom severity (Bär, 2015). While all APs 
possess a propensity via potassium channel blockade to prolonged QTc interval on 
ECG, and a potential to cause life-threatening arrhythmias, the risk is most relevant 
with ziprasidone and sertindole of all compounds currently used in Finland (Nielsen 
et al., 2011a). Many APs have tachycardia-inducing properties, mediated both 
directly by blockage of the type 2 muscarinic receptors in the heart (anticholinergic 
effect) , and indirectly (reflex tachycardia) by anti-α1 adrenergic effect in the blood 
vessels resulting in vasodilatation (Buckley and Sanders, 2000). Clozapine may 
rarely cause severe cardiac complications, myocarditis and cardiomyopathy, yet the 
most common and usually benign cardiac side effect of clozapine is persistent 
tachycardia (Nielsen et al., 2013).  
Individuals with schizophrenia have been shown to be less often admitted to 
hospital care and receive invasive procedures for coronary heart disease compared to 
those without mental illness (Manderbacka et al., 2012,Mitchell and Lawrence, 
2011). In addition, prescription rates for basic medications (ACE inhibitors, beta-
blockers, statins and non-aspirin anticoagulants) for primary or secondary prevention 
of CV diseases have been shown to be inferior in patients with schizophrenia 
compared to patients without mental illness (Mitchell et al., 2012b). 
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2.2.5 RESPIRATORY DISEASES 
Despite high rates of smoking and obesity predisposing patients with schizophrenia 
to respiratory symptoms and diseases, the topic has gained quite limited interest in 
research of somatic comorbidities. In the studies included in a review of somatic 
comorbidity in schizophrenia, the prevalence of chronic obstructive pulmonary 
disease ranged from 22.6-31% (Oud and Meyboom-de Jong, 2009), whereas a recent 
US schizophrenia register study revealed a prevalence of 10.2% for chronic 
obstructive pulmonary disease, emphysema and asthma (Nasrallah et al., 2015). 
Moreover, a large Taiwanese study established a 30% increased risk for asthma in 
individuals with schizophrenia (Chen et al., 2009). Partti et al. evaluated several 
aspects of respiratory health in the PIF Study, and showed that a third of the 
schizophrenia sample had impaired lung function (both restriction and obstruction) 
using spirometry. In addition, the odds for chronic obstructive pulmonary disease 
and chronic bronchitis were fourfold higher compared to the general population 
(Partti et al., 2015). Elevated risk for chronic obstructive pulmonary disease and 
substantially increased mortality due to it were also established in a large scale 
Swedish register study (Crump et al., 2013).  
2.2.6 DENTAL DISEASES 
Poor oral health is a risk factor for severe infections and CV diseases (Buhlin et al., 
2011). Patients with schizophrenia have several risk factors for developing dental 
diseases: neglected oral hygiene, dry mouth due to anticholinergic medication use, 
smoking and eating/drinking sugary food products (McCreadie et al., 2004,Persson 
et al., 2009,Moore et al., 2015). 
A meta-analysis of dental problems in patients with a SMI, comprising mainly 
patients with a diagnosis of schizophrenia, demonstrated that total tooth loss was 
over three times and signs of dental caries over twice as common as in the controls 
(Kisely et al., 2011). In a Danish database study on dental visits of patients with 
schizophrenia, a lower rate of regular check-ups by a dentist was found in the 
schizophrenia group: males, inpatients, forensic patients and patients with comorbid 
substance abuse had a higher risk for inappropriate dental assessment (Nielsen et al., 
2011b).  
2.2.7 CANCER  
Despite the fact that individuals with schizophrenia have a notable amount of 
common risk factors for malignant diseases (smoking, obesity, lack of physical 
exercise), epidemiological studies have found conflicting results concerning the 
prevalence of cancer: some show similar, some increased and some even a decreased 
risk for cancer compared to the general population. Accordingly, a meta-analysis 
found no increase in cancer incidence in patients with schizophrenia (Catts et al., 
2008). Explanations for this phenomenon include methodological differences across 
the studies, the overall shortened life expectancy due to competing causes of death 
and lower cancer screening rates in schizophrenia (De Hert et al., 2011b).  
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Nevertheless, in a recent Swedish population-based follow-up study, patients 
with schizophrenia had a higher mortality rate, especially from lung, breast and 
colon cancers compared to the general population, but also a lower risk of being 
diagnosed with cancer, pointing to underdetection of these diseases (Crump et al., 
2013). Accordingly, a large US register cohort study established an increased 
mortality risk due to tobacco-related cancers in people with schizophrenia compared 
to controls (Callaghan et al., 2014). According to a review, people with 
schizophrenia often encounter difficulties in the detection, treatment and palliative 
care of cancer (Irwin et al., 2014).  
2.2.8  DISEASES OF THE DIGESTIVE SYSTEM  
Constipation is a typical adverse effect of several AP drugs, and patients using 
clozapine are especially prone to it (Correll et al., 2015). Drug induced 
anticholinergic effect on the gut by the blockage of muscarinic receptors resulting in 
decreased bowel motility is the main cause for constipation in AP medicated 
patients. Additionally, effects on histamine 1 and serotonin receptors may also play a 
role (Nielsen, Meyer, 2012). Moreover, other medications used by patients and low 
physical activity, due to the illness itself or to sedation, may predispose patients to 
constipation. A recent systematic review and meta-analysis showed a 31.2% 
prevalence of constipation among clozapine users, and a 3-fold risk for constipation 
compared to the users of other APs (Shirazi et al., 2016). Complications of 
constipation due to clozapine treatment have been shown to have an almost 10-fold 
higher case fatality rate compared to agranulocytosis, i.e. more clozapine users die 
due to severe consequences of constipation than due to agranulocytosis (Cohen et al., 
2012). In addition to the possible negative impact on the gut, clozapine has been 
shown to have the potential to cause hypomotility of the entire gastrointestinal tract 
that may, for example, result in dysphagia (Palmer et al., 2008). 
Constipation may lead to fatal consequences: ileus, bowel obstruction and 
ischaemia leading to perforation, peritonitis and sepsis (Nielsen and Meyer, 
2012,Hibbard et al., 2009). A recent Japanese 2-year follow-up study on ileus among 
psychiatric patients (with no clozapine users in the sample) showed that ileus 
relapsed in almost half of the cases in patients with schizophrenia. Older patients 
especially and those who had undergone abdominal surgery had a high risk for 
relapse (Kitahata et al., 2016).  
A psychiatric hospital survey assessing symptoms of dyspepsia in a sample in 
which 61% patients had a psychotic illness and 80% were using APs revealed that 
80% of the sample had one or more dyspeptic symptoms (Mookhoek et al., 2005). In 
addition, a British study based on psychiatric outpatient prescription data showed 
that antacid use was over three times more prevalent in clozapine users compared to 
users of other SGA (Taylor et al., 2010). Furthermore, some evidence exists linking 
coeliac disease (Kalaydjian et al., 2006) and irritable bowel syndrome (Garakani et 
al., 2003) to schizophrenia.  
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Non-alcoholic fatty liver disease in schizophrenia has been scarcely studied, 
although there is an epidemic of obesity and MetS among these patients. A US 
database study examining hepatic diseases in SMI, revealed a fourfold risk for 
having diagnosed alcoholic cirrhosis and 7.5-fold risk for non-alcoholic fatty liver 
disease compared to controls (Fuller et al., 2011). Clozapine has been associated 
with hepatic reactions of varying degree: from severe liver failure to mild and 
reversible transaminase increase (Nielsen et al., 2013).  
2.2.9 DISEASES OF THE EAR AND HEARING IMPAIRMENT 
A recent meta-analysis studying associations between impaired hearing and 
psychotic symptoms, delirium and development of schizophrenia, showed an 
increased risk for all of these conditions among participants with hearing difficulties 
(Linszen et al., 2016). Among older adults hearing impairment is a classic risk factor 
for psychosis (Almeida et al., 1995). Accordingly, self-reported hearing impairment 
in adolescence was shown to double the risk for psychotic symptoms in a 10-year 
follow-up (van der Werf et al., 2011). In addition, significant hearing impairment 
was shown to associate with an almost 2-fold risk for later development of 
schizophrenia in a cohort of 50 000 Swedish conscripts (David et al., 1995). 
Furthermore, in a Dutch general population sample, deafness or hearing impairment 
was associated with positive psychotic experiences in a 3-year follow-up (Thewissen 
et al., 2005). There is some evidence that middle ear disease like otitis media may be 
a risk factor for schizophrenia, the authors of the paper speculating the underlying 
mechanism of temporal lobe irritation by the infection (Mason et al., 2008).  
Diseases of the ear and hearing difficulties have been rarely studied in 
established schizophrenia. The World Health Survey conducted by WHO examined 
self-reported problems in hearing and showed over a 2-fold risk among persons with 
a psychosis diagnosis and symptoms (Moreno et al., 2013). In the PIF Study 
individuals with schizophrenia reported more difficulties in hearing conversations, 
especially in noisy environments, compared to controls. The prevalence of hearing 
impairment, measured by audiometry, did not differ in persons with a psychotic 
disorder compared to the general population (Viertiö et al., 2014). In line with the 
PIF study, geriatric patients with schizophrenia reported difficulties in hearing more 
commonly but did not differ in the audiometry from the controls (Prager and Jeste, 
1993). Results from a Scottish general practice database study showed a somewhat 
higher prevalence of hearing loss in schizophrenia compared to controls (Smith et 
al., 2013). 
Cerumen (“earwax”) is a physiological substance lubricating and protecting the 
skin of the ear canal. Sometimes it causes problems by accumulating and resulting in 
occlusion, i.e. cerumen impaction (Table 6). Cerumen impaction is a common reason 
to visit primary care (Mitka, 2008,Burton and Doree, 2009). Total occlusion of the 
ear canal results in a 40 decibel decrease of hearing threshold (Roeser and 
Ballachanda, 1997). According to WHO, disabling hearing loss is considered in 
adults when the hearing threshold is decreased more than 40 decibels in the better 
ear (WHO World Health Organization, 2017a). As an example, whispering from a 
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distance of 1 metre results in 40 decibels. High rates of cerumen impaction have 
been shown in geriatric (Mahoney, 1993) and intellectually impaired populations 
(Crandell and Roeser, 1993). Removal of cerumen impaction has been shown to 
improve hearing in healthy individuals (Subha and Raman, 2006), and cognition in 
geriatric patients with cognitive decline (Oron et al., 2011,Sugiura et al., 2014). 
Prevalence of cerumen impaction in the general adult population is about 5% 
(Roland et al., 2008). The phenomenon has not been previously studied in 
schizophrenia. Individuals with cognitive impairment may not recognize cerumen 
impaction and impaired hearing, which suggests that there is a need to evaluate ear 
canals of specific populations (Roland et al., 2008). 
 
Table 6. Features of cerumen impaction according to Roland et al., 2008 and Burton and Doree, 
2009. 
Aetiology Failure in self-cleaning mechanism of the ear canal leads to accumulation of 
glandular secretions and exfoliated squamous epithelium, resulting in 
occlusion  
Predisposing 
factors 
Anatomically narrow ear canal, using a hearing aid or cotton buds, 
dermatological diseases, reduced glandular secretion due to advanced age 
Symptoms Impaired hearing, tinnitus, pain, dizziness, cough 
May also be asymptomatic, especially in persons with cognitive problems 
Treatment Cerumenolytic agents, irrigation of ear canal, manual removal 
 
2.2.10 INFECTIONS 
Despite the high mortality rate from infections in schizophrenia (Saha et al., 
2007,Crump et al., 2013,Nordentoft et al., 2013,Ribe et al., 2015), the role of 
infectious diseases has gained limited attention in research except for the role of 
infections as an aetiological factor in schizophrenia.  
Several risk factors for community-acquired pneumonia are common in 
individuals with schizophrenia, including smoking, alcohol abuse, poor dental 
hygiene, chronic respiratory diseases and diabetes (Torres et al., 2013). Risk for a 
person with schizophrenia of having been diagnosed with pneumonia or influenza 
was almost doubled, and the risk of death due to the aforementioned diseases almost 
seven times higher compared to the general population in Sweden between 2003-
2009 (Crump et al., 2013). Furthermore, participants with schizophrenia had fivefold 
odds of having been hospitalized due to pneumonia compared to controls in the PIF 
Study (Partti et al., 2015). An elevated risk for pneumonia in individuals with 
schizophrenia was established among patients using clozapine, and a moderate risk 
associated with most other SGA medications, in a large Taiwanese database study 
(Kuo et al., 2013). The elevated risk of pneumonia associated with AP use is thought 
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to be mediated by anticholinergic and antihistaminergic side effects of these 
medications (Kuo et al., 2013). When hospitalized due to pneumonia, patients with 
schizophrenia have been shown to have more complications (e.g. more acute 
respiratory failures, need for mechanical ventilation or intensive care unit 
admissions) in treatment compared to controls (Chen et al., 2011). In addition to 
pneumococcal pneumonia, a twofold risk for pneumococcal septicaemia and 
meningitis was found in patients with SMI in a study using British nationwide 
hospital datasets (Seminog and Goldacre, 2013). 
Viral hepatitis had the highest (fourfold) odds of individual somatic diagnoses in 
patients with schizophrenia compared to control subjects in a Scottish GP database 
study examining somatic comorbidities of almost 10 000 patients with schizophrenia 
spectrum disorders (Smith et al., 2013). Blood-borne viral infections are mostly 
transmitted by intravenous drug use and unprotected sex. Recently individuals with 
SMI were shown to have pooled prevalence of hepatitis B (2.7%), C (4.9%) and HIV 
(1.9%) in the European studies included in the review (Hughes et al., 2016). 
Whereas in a Danish population-based register study, the risk of HIV was not 
elevated in individuals with schizophrenia without substance misuse disorders, 
individuals with HIV had a higher risk for schizophrenia (Helleberg et al., 2015). 
High probability for urinary tract infections has been shown in relapsed patients 
with schizophrenia compared with stable outpatients and healthy controls (Miller et 
al., 2013).  
Individuals with microdeletion in chromosome 22, resulting in velocardiofacial 
syndrome and frequently thymic aplasia/hypoplasia (among several other 
developmental anomalies), have a 6-30-fold increased risk of developing 
schizophrenia (Kobrynski and Sullivan, 2007). Velocardiofacial syndrome is often 
associated with immunodeficiency by both impaired T- and B-cell functions leading 
to recurrent infections (Davies, 2013). It is important to keep in mind the possibility 
of velocardiofacial syndrome in patients with schizophrenia having frequent 
infections, facial dysmorphic features and cognitive impairment.   
2.2.11 BONE HEALTH AND VITAMIN D DEFICIENCY 
An increased rate of fractures in schizophrenia was shown in a recent systematic 
review and meta-analysis, and the authors especially pointed out the effect of 
prolactin-raising antipsychotic medications on fracture risk along with other typical 
risk factors in this population, e.g. low muscle strength, impaired balance and 
sedentariness (Stubbs et al., 2015a). Smoking, a diet with low vitamin D, K and 
calcium, excessive consumption of caffeine, salt or alcohol and lack of sunlight may 
also play a role in development of osteoporosis in patients with schizophrenia 
(Kishimoto et al., 2012). According to another meta-analysis by Stubbs et al., 
individuals with schizophrenia had a 2.5-fold risk for osteoporosis compared to the 
general population, and risk for reduced bone mass was even higher (Stubbs et al., 
2014). In the PIF sample, women with schizophrenia had lower values in calcaneal 
ultrasound measures compared to controls, as a proxy for worse bone health (Partti 
et al., 2010). 
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Vitamin D deficiency is an established risk factor for muscular weakness and low 
bone mineral density. Furthermore, it has been linked to several other conditions and 
illnesses (CV and neurological diseases, infections, cancer etc.). Increased vitamin D 
deficiency among patients with schizophrenia has been revealed in two meta-
analyses (Belvederi Murri et al., 2013,Valipour et al., 2014). In addition, a British 
case control study showed that lower vitamin D levels were present in white and 
black patients with FEP compared to controls (Crews et al., 2013). Another recent 
study from the UK showed that only one in eight (14%) of patients with an 
established psychotic disorder had sufficient (>50nmol/l) concentration of vitamin 
D, and interestingly, vitamin D deficiency was associated with physical inactivity, 
presence of MetS and elevated C-reactive protein (Lally et al., 2016). Lower vitamin 
D levels compared to the general population were also seen in the PIF schizophrenia 
sample (Partti et al., 2010).  
2.2.12 OTHER COMORBIDITIES 
Urinary complaints may cause problems in hygiene and self-care, and confusion, at 
least in older people. In a survey of psychiatric inpatients, 60% of respondents with 
schizophrenia reported urinary incontinence (bed-wetting, leakage), and higher 
prevalence of the aforementioned symptoms compared to patients with mood 
disorders from the same hospital (Bonney et al., 1997).  
Risk for development of chronic kidney disease was increased in patients with 
schizophrenia compared to matched controls in a Taiwanese 3-year register follow-
up study, and the association was especially pronounced in patients using non-
steroidal anti-inflammatory drugs (NSAIDs), older patients and those with diabetes 
(Tzeng et al., 2015). Another Taiwanese study showed that patients with a 
combination of schizophrenia and advanced renal disease received a lower standard 
of care in pre-dialysis stage, and had higher hospitalization and mortality rates after 
the initiation of dialysis compared with controls (Hsu et al., 2015). Renal problems 
associated with lithium use include nephrogenic diabetes insipidus and chronic 
kidney disease(Rej et al., 2016). Dehydration (e.g. due to gastroenteritis) and drug 
interactions (e.g. NSAID use) in particular may lead to increased concentrations of 
lithium and subsequent renal damage. Pathophysiological mechanisms leading to 
chronic nephropathy in lithium use are not well understood(Rej et al., 2016). 
Nevertheless, this mood stabilizer is used infrequently in schizophrenia, whereas 
APs do not cause adverse renal effects (Correll et al., 2015).  
Medications used to treat mood symptoms in schizophrenia may increase the risk 
for other somatic adversities as well. Hyponatremia may occur due to selective 
serotonin reuptake inhibitor-induced inappropriate secretion of antidiuretic hormone, 
or as a result of polydipsia (Correll et al., 2015). In turn, a common side effect of 
lithium is hypothyroidism, but a less well known is hyperparathyroidism and 
subsequent hypercalcemia (McKnight et al., 2012).  
In a study examining administrative claims data from both in- and outpatient 
healthcare providers in the US, persons with schizophrenia had increased odds for 
electrolyte disturbances, hypothyroidism and anaemia (Carney et al., 2006).  
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According to a review, 16-60% of patients with schizophrenia report sexual 
dysfunction (de Boer et al., 2015). APs (mainly by hypogonadism due to dopamine 2 
receptor antagonism and hyperprolactinemia) and also selective serotonin reuptake 
inhibitor medications may cause sexual side effects (Rizvi and Kennedy, 2013,de 
Boer et al., 2015). Nevertheless, hyperprolactinemia may occur in the AP-naïve 
phase of schizophrenia (Gonzalez-Blanco et al., 2016). In addition, psychiatric 
symptoms, psychological or social problems like previous negative experiences, 
stigmatization and challenging living conditions, i.e. lack of privacy in hospitalized 
individuals or those living in sheltered housing, may endanger sexual health (De 
Boer et al., 2015).  
Associations between dermatological diseases and schizophrenia have been 
scarcely studied. In a German outpatient database study, persons who had received 
treatment for atopic eczema were shown to have 2-fold odds of having a comorbid 
schizophrenia spectrum diagnosis (Schmitt et al., 2009).   
In the PIF Study, near and distant vision were examined by visual charts using 
subjects´ own eyeglasses (if any), and the odds for visual impairment was shown to 
be 5 to 6-fold in persons with schizophrenia compared to controls from the general 
population (Viertiö et al., 2007). The demonstrated, highly prevalent visual 
impairment may have been caused by lack of appropriate visual correction with 
adequate spectacles, given that the individuals with schizophrenia had undergone 
visual examination during the previous five years more seldom than the controls 
(Viertiö et al., 2007). The association of lens opacities and schizophrenia has been 
noted decades ago (Greiner and Berry, 1964), and APs especially from the 
phenothiazine group have been suggested to cause cataracts (Isaac et al., 1991). 
Interestingly, a recent Taiwanese case control study from a national health insurance 
database did not show an association between cataracts and SGA, but instead found 
an association between caratacts and simultaneous antidepressant use (Chou et al., 
2016). In all, there is a complicated interplay between the schizophrenia illness 
itself, mainly anticholinergic side effects of AP medications, and the manifestation 
of comorbid somatic illnesses (e.g. T2D) in ocular health/visual impairment 
(Silverstein and Rosen, 2015). 
2.3 RISK FACTORS FOR SOMATIC COMORBIDITY  
2.3.1 MEDICATION 
Medications used in the treatment of schizophrenia may lead to several somatic 
problems by interfering with receptor binding in both the central and the peripheral 
nervous systems, and directly in the tissues and organs as well. As discussed 
previously, psychotropic medications have been associated with weight gain, MetS, 
T2D, infections and cataracts, along with CV, dental, gastroenterological, renal, 
sexual and endocrinological adversities. 
Often troublesome and potentially dangerous anticholinergic side effects of the 
autonomic nervous system may be forgotten in clinical practice and in research. 
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Typical anticholinergic side effects are blurred vision, constipation, dry mouth, dry 
skin, urinary retention, tachycardia and confusion (Ozbilen and Adams, 2009). In 
addition, anticholinergic drugs are associated with cognitive problems (Uusvaara et 
al., 2013). Especially FGA, and also SGA, medications may cause them. In addition, 
tricyclic antidepressants and some other antidepressants and many somatic 
medications possess anticholinergic properties. Anticholinergic effects are mostly 
mediated by blockage of the muscarinic receptors resulting in decreased effect of 
acetylcholine in the target organ. Several self-rating scales for drug-induced side 
effects exist: one (for mainly anticholinergic side effects) designed for FGA users 
(Day et al., 1995), a general checklist also suitable for SGA users (Haddad et al., 
2014) and a specifically tailored scale for clozapine users (Hynes et al., 2015).  
2.3.2 UNHEALTHY LIFESTYLE 
In this thesis, the concept “lifestyle” comprises habits of an individual that have 
implications for health, e.g. diet, physical activity, smoking and alcohol 
consumption.      
Diet 
Diet influences development of obesity, T2D, dental and CV diseases. In Finland, a 
major reduction in CV mortality has been observed since the 1970s. The most 
important cause for this reduction is lowered cholesterol levels mirroring a diet 
change at population level (Jousilahti et al., 2016). Studies on dietary patterns in 
schizophrenia are mainly from retrospective self-report data, e.g. 24-hour diet recall 
questionnaires or interviews, as done in the general population. With this method, 
under-reporting of energy has been shown to occur, especially by obese respondents 
(Kye et al., 2014,Ratliff et al., 2012). According to a review of thirty-one 
methodologically heterogeneous studies, people with schizophrenia were shown to 
have unhealthy eating patterns: high intake of saturated fat and low consumption of 
fibre and fruit compared to controls, in two studies caloric intake was increased in 
the schizophrenia group. However, the majority of studies in the review did not 
collect information on portion size, i.e. energy intake (Dipasquale et al., 2013).  
Smoking and alcohol  
Smoking is an established risk factor for several diseases, e.g. chronic obstructive 
lung disease, cardiovascular diseases, cancer, T2D, bone fractures and 
periodontitis/missing teeth (Willi et al., 2007,Vestergaard and Mosekilde, 
2003,Nociti et al., 2015,Forey et al., 2011). In Finland 4000-6000 people die 
prematurely due to tobacco smoking annually (The Finnish Medical Society 
Duodecim and the Finnish Association for General Practice, 2012). In schizophrenia, 
smoking also contributes to high mortality rates (Suvisaari et al., 2013a,Callaghan et 
al., 2014,Dickerson et al., 2016).  
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Because of the high rates of tobacco dependence and the detrimental effect of 
smoking to the health and life expectancy of individuals with schizophrenia 
(Dickerson et al., 2016), smoking cessation is strongly promoted as part of 
psychiatric care in guidelines by the European Psychiatric Association, NICE, PORT 
and the Finnish Current Care (Ruther et al., 2014,National Institute for Health and 
Care Excellence, 2014,The Finnish Medical Society Duodecim and the Finnish 
Psychiatric Association, 2015). In addition to adverse effects on health, smoking 
causes notable economic disadvantage, especially for individuals with low income.  
A strong association exists between smoking and schizophrenia. Individuals with 
schizophrenia are more often smokers and possess higher nicotine dependency (de 
Leon and Diaz, 2005). In a US study from 2011, 64% of the participants with 
schizophrenia vs. 19% of those without a psychiatric disorder reported current 
smoking (Dickerson et al., 2013). Interestingly, the quantity of smoked cigarettes 
was not associated with psychiatric symptom severity measured by the Positive and 
Negative Syndrome Scale (Dickerson et al., 2013). Patients with schizophrenia in the 
PIF Study reported daily smoking almost twice as often (44% vs. 23%) and more 
heavily compared to the general population (Partti et al., 2015). In addition, 
reflecting the high nicotine intake, participants with schizophrenia had higher serum 
levels of major nicotine metabolite cotinine, compared with the participants without 
psychosis (Partti et al., 2015).  
The possible reasons for high rates of smoking among individuals with 
schizophrenia are numerous. Risk factors such as poverty, low education level and 
environments lacking support to stay, or become, smoke free may have an impact on 
initiation of smoking and endanger patients´ attempts to quit (Tidey and Miller, 
2015). There is also some evidence that schizophrenia and nicotine dependency may 
share common genetic pathways (Loukola et al., 2014). The most popular 
aetiological explanation for the association between smoking and schizophrenia has 
been the so-called self-medication hypothesis: smoking releases dopamine from the 
brain, and patients using AP medications are thought to alleviate their 
extrapyramidal side effects, as well as negative symptoms, by smoking (Ruther et 
al., 2014). However, because of a strong financial contribution from the tobacco 
industry to smoking research regarding the self-medication hypothesis in 
schizophrenia, the reliability of that evidence has been questioned (Prochaska et al., 
2008). Interestingly, there is suggestive evidence that smoking (Gurillo et al., 
2015,Kendler et al., 2015,Laursen and McGrath, 2016) and foetal exposure to 
maternal smoking (Niemelä et al., 2016) may be risk factors for the development of 
a psychotic illness later in life. 
According to a meta-analysis, alcohol use disorders are quite common in 
schizophrenia (current prevalence 9%, lifetime prevalence 21%) (Koskinen et al., 
2009). Alcohol is an established risk factor for several somatic diseases: liver 
diseases, pancreatitis, gastroenterological cancers, hypertension, atrial fibrillation, 
and especially heavy drinking for T2D, infections and injuries (WHO World Health 
Organization, 2014a). In the PIF Study, however, participants with schizophrenia 
used less alcohol than the general population comparison group (Suvisaari et al., 
2007). The mean duration of illness in the schizophrenia group was almost 20 years, 
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suggesting that over the course of illness alcohol use-related problems become less 
common in patients with schizophrenia, at least in Finland (Suvisaari et al., 2009). 
 
Physical activity 
 
Sedentary lifestyle is associated with increased mortality and morbidity from T2D, 
CV disease, breast, and colon cancer (Lee et al., 2012). In addition, long sitting time 
substantially increases the odds of having MetS (Edwardson et al., 2012). A recent 
meta-analysis of sedentary behaviour in people with schizophrenia demonstrated 
high sedentary patterns among them compared to controls, and that using an 
objective device (e.g. accelerometer) as a measure, instead of self-report 
information, doubled the time spent sitting to over 12 hours per day in the analysis 
(Stubbs et al., 2016). CV comorbidity, negative symptoms, lower socioeconomic 
status, longer illness duration, frequent hospitalizations, medication side effects and 
lack of social support have been shown to predict reduced physical activity in 
schizophrenia (Vancampfort et al., 2012a). In turn, low self-reported physical 
activity and reduced performance in a 6-minute walk test, have been defined as 
predictors for lower physical health-related quality of life in patients with 
schizophrenia (Vancampfort et al., 2011a).  
2.3.3 FACTORS ASSOCIATED WITH PSYCHIATRIC ILLNESS 
 
Patient level 
 
Cognitive and negative symptoms, suspiciousness, social isolation and difficulties in 
social interaction may hinder patients with schizophrenia from noticing, seeking and 
receiving help for somatic problems (De Hert et al., 2011a). In addition, 
unawareness of physical problems may sometimes be attributed to lack of insight, 
for example, when a patient has obvious dermatological or dental pathologies.  
Self-efficacy is a concept based on social cognitive theory, and it is defined as 
the confidence of a person about his/her own ability to succeed in particular 
situations or to accomplish tasks (Bandura, 1977). In turn, a certain level of self-
efficacy is essential for self-care. Perceived discrimination and a pattern of self-
stigmatization among people with schizophrenia have been shown to correlate with 
lower self-efficacy (Vauth et al., 2007). In a study on T2D patients, those with 
schizophrenia had a lower level of self-efficacy and worse diabetes self-care 
compared to non-psychiatric patients, and one particularly important predictor for 
lower self-care was lower scoring in a self-efficacy scale (Chen et al., 2014).   
Difficulties in several everyday functional abilities and limitations in mobility 
have been shown to be more prevalent in schizophrenia compared to age- and 
gender-adjusted controls from the general population (Viertiö et al., 2012,Viertiö et 
al., 2009). These specific challenges may also contribute to a lower level of somatic 
self-care. 
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In a recent meta-analysis of experimental studies, persons with schizophrenia, 
both AP medicated and medication-free, were shown to have a higher pain threshold 
compared to controls, the authors speculating the decreased sensitivity to pain as a 
potential endophenotype of schizophrenia (Stubbs et al., 2015b). The reason for 
decreased pain sensitivity in schizophrenia is not clear, but presumably altered 
neurobiological functioning plays an important role (Stubbs et al., 2015b). 
Moreover, striking case reports of severe and life-threatening conditions exist 
(Agorastos et al., 2011). Insensitivity to pain, often combined with symptoms related 
to the psychotic illness itself, may lead to under-recognition and marked delays in 
help-seeking and treatment of physical illnesses.  
People with schizophrenia usually have low income, as most of them are on a 
disability pension. Furthermore, many of them have a low education level and are 
single (Suvisaari et al., 2013). These sociodemographic factors have been shown to 
associate with adverse heath outcomes in the general population (Joutsenniemi et al., 
2006,Palosuo et al., 2009). 
 
System level 
 
Several barriers exist for individuals with schizophrenia to receive help for somatic 
problems from health services: lack of services that would reduce the gap between 
somatic and psychiatric care, unawareness of who should be responsible for the 
somatic healthcare, under-resourcing in services, and in some countries, worse 
health insurance coverage (De Hert et al., 2011a).   
Stigma is a common feature related to SMI containing three elements: lack of 
knowledge, negative attitudes and discriminative behaviour (Thornicroft et al., 
2007). In a study examining the attitudes of healthcare professionals using patient 
case vignettes, the researchers showed that the participants judged a hypothetical 
patient with multiple somatic complaints and diagnosis of schizophrenia to be less 
adherent to treatment, and less competent to understand educational material to make 
decisions concerning treatment. In addition, the providers were less ready to send “a 
schizophrenic patient” to a weight control programme compared to a similar patient 
case without schizophrenia (Sullivan et al., 2015). Another study examining attitudes 
towards patients with SMI showed that the nurses felt patients with schizophrenia 
were different from other people, potentially dangerous, unpredictable and hard to 
communicate with (Björkman et al., 2008).  
Table 7 summarizes the risk factors for somatic comorbidity in schizophrenia. 
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Table 7. Risk factors for somatic comorbidity in schizophrenia. 
Symptoms of 
schizophrenia 
Positive, negative, disorganized and cognitive symptoms, reduced 
pain sensitivity (leading to social isolation, difficulties in insight, 
communication and self-care) 
 
Lifestyle  Smoking, unhealthy diet, sedentariness, substance abuse, 
unprotected sexual behaviour 
 
Psychotropic 
medications 
Metabolic, endocrine, cardiac and anticholinergic side effects, 
hyperprolactinemia, sedation 
 
Socioeconomic factors Poverty, low levels of education and employment, lack of social 
support (being single) 
 
System-related factors Lack of monitoring, prevention and treatment of somatic risk factors 
and comorbidities, separation of medical and psychatric services, 
lack of resources and knowledge to take care of patients’ somatic 
well-being in psychiatric facilities, difficulties in accessibility to 
primary healthcare, stigmatization  
 
 
According to Leucht et al., 2007 and De Hert et al., 2011a 
2.3.4 COMMON AETIOLOGICAL MECHANISMS: INFLAMMATION 
Inflammation is an adaptive response to any condition perceived as potentially 
dangerous to the host, and can be caused by a pathogen or an injury (Lugrin et al., 
2014). Prolonged inflammatory state, low grade inflammation, is observed in several 
psychiatric and somatic illnesses, and it participates in the pathogenesis of diseases, 
e.g. T2D (Pradhan et al., 2001). Individuals with psychoses, severe depression and 
bipolar disease have been shown to have increased serum levels of several 
proinflammatory cytokines (Manu et al., 2014a). Cytokines are messenger molecules 
of the immune system and are among the key coordinators of inflammatory 
response, e.g. excessive visceral adipose tissue secretes proinflammatory cytokines.  
Inflammation and immune dysfunction may represent both a causative and a 
secondary phenomenon in schizophrenia (Suvisaari and Mantere, 2013b). Genetic 
studies suggest that there may be some aetiological overlap. For example, alleles of 
complement component 4 gene that are associated with higher expression of 
complement 4 are associated with an increased risk of schizophrenia (Sekar et al., 
2016). However, the current evidence is not yet sufficient to draw an aetiological 
causality between them, and inflammation in schizophrenia may also relate to other 
factors, such as obesity and psychological stress, that are common in SMI (Manu et 
al., 2014a).  
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2.4 ASSESSMENT OF SOMATIC COMORBIDITY 
A growing body of evidence on somatic comorbidity in schizophrenia, especially on 
metabolic issues, has led to the development of international and local guidelines on 
the monitoring of somatic parameters. De Hert et al. evaluated 18 such guidelines 
published between 2004 and 2010 with a special instrument “Appraisal of 
Guidelines for Research and Evaluation”, and found that the guidelines varied 
notably (De Hert et al., 2011d). Most guidelines focused on the monitoring of CV 
and diabetes risk factors, some also included assessment of other somatic disorders. 
Guidance in the timing for monitoring of laboratory parameters and weight varied. A 
half of the guidelines mentioned the need for regular physical examination. Most 
guidelines suggested that the doctor prescribing psychiatric medication should be 
responsible for the monitoring, whereas involvement of a GP was stated in only one 
third of the guidelines. Promotion of a healthy diet and physical activity was 
mentioned in most guidelines but usually lacked practical suggestions on how the 
targets could be accomplished. In addition, education of healthcare professionals to 
implement the suggested interventions was missing in the majority of guidelines. 
Table 8 shows suggestions regarding physical health in Finnish and British 
guidelines for schizophrenia. 
A systematic evaluation and meta-analysis on studies reporting metabolic 
screening (weight, lipids, glucose, blood pressure) in patients using AP medications 
reported the screening rates in general, and the effect of monitoring guidelines on the 
screening rates (Mitchell et al., 2012a). The researchers defined monitoring to be 
inadequate if less than half of the target population received it, and good to optimal 
if over 80% of the sample were monitored. In the post-guideline time points about 
three-quarters of the patients were monitored for weight and blood pressure, one half 
for glucose and less than one third for lipids. A modest increase in glucose 
monitoring rate after the guideline implementation was observed (Mitchell et al., 
2012a).  
 A national audit in England and Wales on treatment of schizophrenia has been 
made twice (2011 and 2014) in order to examine the quality of secondary psychiatric 
care using standards taken from the National Insititute for Health and Care 
Excellence (NICE) guidelines (Royal College of Psychiatrists, 2014). The audits 
evaluate several aspects of care, one of which is monitoring and intervention for 
physical health problems. The data is derived from service users and their carers, 
psychiatric patient records and, if needed, from primary care records. Both audits 
showed an inadequacy in screening and intervention in somatic domains, e.g. in 
about half of the sample an annual BMI measurement was missing in the health 
records, and only one third of patients with deviant glucose measurement had 
received an intervention (Royal College of Psychiatrists, 2014).  
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Table 8. Suggestions for somatic monitoring in two schizophrenia treatment guidelines.  
 
Current 
care 2015 
 
Finland 
 
Weight: Monitor and document at onset, then regularly, emphasized in clozapine 
and olanzapine use. Important to thrive for weight management from the beginning 
of psychotic illness. Metformin may be considered for weight control 
 
Fasting glucose, lipids: Monitor and document at onset, 3 months, one year, 
annually. Evaluate predisposing familial risk and health habits for metabolic 
disturbances 
 
Smoking: Evaluation of smoking status in first-episode psychosis. Combination of 
nicotine replacement and cognitive behavioural therapy may help patients to quit 
 
Lifestyle in general: Evaluation in first-episode psychosis. Important to promote a 
healthy lifestyle. Wellness training may help patients in achieving changes in health 
habits and reduce cardiovascular risk. Consider prevention of somatic illnesses in 
stable phase of psychiatric illness 
 
Responsibility for monitoring: Prevention and treatment of somatic illnesses in 
primary care. Important: collaboration between primary and psychiatric care in 
prevention, detection and treatment of somatic illnesses. In the system level 
suggested to monitor the proportion of patients having undergone an evaluation of 
somatic risk factors and long-term illnesses 
 
NICE 
2014  
 
UK 
Weight*: Monitor and record at onset, weekly for 6 weeks, at 3 months, one year, 
annually 
 
Fasting glucose, lipids*: Monitor and record at onset, 3 months, one year, 
annually 
 
Smoking: Offer patients help to stop smoking. Be aware of the possible impact to 
drug metabolism in the quitting phase. Consider pharmacological compounds as a 
quitting aid, monitor patients with bupropion and varenicline for adverse 
neuropsychiatric events. Offer nicotine replacement for inpatients not willing to quit 
 
Lifestyle in general*: A healthy eating and physical activity programme should be 
offered in mental healthcare, especially for patients taking antipsychotics 
 
Responsibility for monitoring: In secondary care, at least first 12 months or until 
the patient is stabilized. Thereafter may be transferred to primary care. Monitor 
overall physical health systematically, at least annually comprehensive health 
checks, results sent to psychiatric unit and included in the patient records. 
Secondary care ensures that a patient has undergone the aforementioned. 
Recommendation to use primary care practice case registers in monitoring the 
health of people with schizophrenia 
*Treatment and/or prevention according to NICE guidelines on Prevention of T2D, Obesity, Lipid 
modification, Prevention of CV diseases and Physical activity 
NICE, National Insititute for Health and Care Excellence 
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2.5 LIFESTYLE INTERVENTIONS  
2.5.1 INTERVENTIONS IN GENERAL 
In the general population promising results have been reported on lifestyle 
interventions in the treatment of obesity (Wadden et al., 2012,Bray et al., 2016) and 
T2D prevention(Schellenberg et al., 2013,Tuomilehto et al., 2001).  
Ward et al. reviewed general population lifestyle programmes that aimed to 
reduce adverse health outcomes, and highlighted that the three key elements in 
successful interventions were dietary change, promotion of physical activity and 
implementation of strategies of cognitive behavioural therapy: goal-setting, self-
monitoring and structured curricula (Ward et al., 2015b). Moreover, it was essential 
that the interventions contained multiple components (not just e.g. diet), 
enhancement of the sense of self-efficacy, long duration, personalized regimens and 
frequent meetings with trained providers. The researchers pointed out that lifestyle 
modification programmes for people with SMI usually lack several of the 
aforementioned elements, and they stated that specific challenges (poverty, 
medication side effects and symptoms due to the psychiatric illness) should be taken 
into account when planning lifestyle interventions for the SMI population (Ward et 
al., 2015b).  
2.5.2 COMPREHENSIVE INTERVENTIONS  
A recent large scale, randomized, high-quality Danish CHANGE study of 450 obese 
participants with schizophrenia spectrum disorders used manualized interventions 
and specially trained lifestyle coaches focusing on several aspects of health (diet, 
smoking cessation, physical activity, care coordination) (Speyer et al., 2015). 
Interestingly, no significant alterations in primary (10-year CV risk score) or 
secondary (cardiorespiratory fitness, weight change, smoking prevalence etc.) 
outcomes were revealed in one-year follow-up (Speyer et al., 2016). The authors 
speculated that the negative results may have resulted from having a study sample 
with few exclusion criteria (chosen in order to optimize the external validity of the 
study) and from the heterogeneity of the interventions in the trial (Speyer et al., 
2016). In the study few of the participants had baseline values of lipids or blood 
pressure indicating a need for change in medication, or had HbA1c values above the 
cut‐off for diabetes, which may reflect the high quality of primary health care for 
patients with schizophrenia in Denmark (Speyer et al., 2016).  
2.5.3 INTERVENTIONS FOR OBESITY 
In prevention and treatment of obesity, it is essential to avoid excessive energy 
intake in relation to expenditure, to make healthy food choices, to maintain physical 
activity, to monitor weight and to react accordingly if the body weight starts to rise 
(Manu et al., 2015). 
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According to a meta-analysis, lifestyle interventions in outpatients with AP-
induced weight gain (diagnoses mentioned in the included trials were mainly 
schizophrenia spectrum disorders) reduced weight by approximately 3kg and 
contributed positively to other outcomes, e.g. waist circumference, blood glucose 
and cholesterol levels (Caemmerer et al., 2012). A more recent meta-analysis of 25 
lifestyle intervention trials in individuals with psychotic disorders showed a large 
effect size for weight gain prevention and a moderate one for weight loss studies, the 
most beneficial interventions were those combining individual and group treatment 
(Bruins et al., 2014). In a 18-month randomized controlled trial (RCT), Daumit et al. 
examined the effects of an intervention focused on changes in diet and physical 
activity in a sample of 279 markedly obese SMI patients (approximately 60% with a 
diagnosis of schizophrenia spectrum disorder), and established in over one third of 
the intervention group a weight loss ≥5%, the mean weight loss being 3.2kg (Daumit 
et al., 2013). Interestingly, almost one in four of the control group lost weight ≥5%, 
presumably due to reduced calorie meals which were made available for all clients in 
the participating rehabilitation facilities (Daumit et al., 2013).  
A recent systematic review on nutrition interventions among individuals with 
SMI demonstrated that significant improvements are achievable in anthopometric 
outcomes and blood glucose level, especially when the intervention is led by a 
dietician and delivered for patients exposed to AP medication for the first time 
(Teasdale et al., 2017). Prevention of AP-induced weight gain has received 
somewhat limited interest in the research. A small study from Australia showed a 
prominent impact of a 12-week intensive preventive lifestyle programme in young 
patients with SMI, 13% of the intervention group experiencing weight gain >7% 
compared to 75% in the control group at the end of the intervention (Curtis et al., 
2016). However, in a prevention study also assessing long-term effectiveness, the 
impact of the 3-month intervention was lost in the 12-months follow-up, suggesting 
a need for a longer period of prevention regimen (Alvarez-Jimenez et al., 2010).  
Furthermore, several medications have been studied in the hope of finding new 
solutions for AP-induced obesity. Metformin has been proposed as a medication 
choice if a non-pharmacological weight loss intervention fails (Correll et al., 
2013,The Finnish Medical Society Duodecim and the Finnish Psychiatric 
Association, 2015). Metformin is recommended as the first treatment in T2D (The 
Finnish Medical Society Duodecim, the Finnish Society of Internal Medicine and the 
Medical Advisory Board of the Finnish Diabetes Society, 2016). It is also a 
treatment option for T2D prevention in prediabetes and in high T2D risk patients 
according to guidelines (American Diabetes Association, 2014,The Finnish Medical 
Society Duodecim, the Finnish Society of Internal Medicine and the Medical 
Advisory Board of the Finnish Diabetes Society, 2016,National Institute for Health 
and Clinical Excellence, 2012). Nevertheless, metformin is infrequently used with 
the preventive indication of T2D (Moin et al., 2015), and has no indication in 
treatment of obesity in the general population. A meta-analysis studying RCTs of 
several medications for AP-induced (mainly olanzapine or clozapine) weight gain, 
showed a mean weight difference in patients using metformin of minus 3kg 
compared to placebo (Mizuno et al., 2014). The most recent meta-analysis on RCTs 
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of metformin treatment for obesity in clozapine patients revealed similar results of 
minus 3.1kg (Siskind et al., 2016). However, a meta-analysis of 21 metformin RCTs 
for AP-induced obesity established more moderate figures: mean differences in 
weight were minus 0.5kg in chronic and minus 0.7kg in FEP patients, and minus 
0.9kg in the included prevention studies (Zheng et al., 2015a).  
The generalizability of the results to Caucasians and African-Americans raises 
some concern. Given that most metformin trials included in the aforementioned 
meta-analyses have been performed outside Europe and the US, the impact of 
ethnicity of the participants was evaluated and found to influence the results: 
Chinese studies showing better effectiveness compared to others (Zheng et al., 
2015a). In addition, the long-term safety of metformin remains unclear in this 
indication and patient population because of the short durations (on average 3 
months, maximum of 6 months) across the trials. Novel meta-analytic evidence 
exists on efficacy of topiramate for non-clozapine AP-induced weight gain 
comparable to metformin (Correll et al., 2016). However, the authors suggest that 
the plausible, undesirable cognitive side effects of topiramate need more thorough 
assessment in the forthcoming studies.  
The choice of the AP compound is important when aiming to prevent weight 
gain. All APs increase the risk of gaining weight in FEP, although with olanzapine 
the risk is most pronounced (Keinänen et al., 2015). US treatment guideline by The 
Schizophrenia Patient Outcomes Research Team (PORT) discourages the use of 
olanzapine as a first line AP in first-episode schizophrenia (Kreyenbuhl et al., 2010). 
Other medications, e.g. mirtazapine, lithium and natrium valproate, also used in the 
treatment of mood symptoms in schizophrenia have a propensity for weight gain 
(Correll et al., 2015). In addition to avoiding certain compounds, dosage may be of 
importance. According to a review, there is preliminary evidence of a positive 
correlation between weight gain and serum concentrations of clozapine and 
olanzapine (Simon et al., 2009). Switching one AP compound to a lower risk one is 
an efficient option in AP-induced obesity (Mukundan et al., 2010). However, the 
risk-benefit ratio of switching must be carefully considered because of the risk of a 
psychosis relapse/worsening of the psychiatric state of the patient.  
2.5.4 INTERVENTIONS FOR SMOKING AND ALCOHOL 
Individuals with schizophrenia are interested in and capable of smoking cessation. In 
a study interviewing people with SMI having succeeded in smoking cessation, the 
majority with schizophrenia spectrum disorders, the participants reported physical 
health concerns, cost of cigarettes and the advice from other people and doctors as 
motivational drivers to stop smoking (Dickerson et al., 2013).  
The European Psychiatric Association recommends that the smoking status and 
potential to quit for patients with mental illnesses should be assessed, and the 
patients should be offered counselling, suggestions for pharmacological support and 
follow-up (Ruther et al., 2014). Interestingly, in a pilot RCT in SMI patients where 
participants received either tailored smoking cessation support from trained mental 
health practitioners or the usual care (i.e. advice to stop smoking and referral to 
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regional services), a third of the participants in the intervention group, and also one 
in four in the control group, managed to be smoke free at 12 months follow-up 
(Gilbody et al., 2015).   
Nicotine replacement therapy, bupropion and varenicline are the recommended 
pharmacological supports in smoking cessation for people with schizophrenia 
(National Institute for Health and Care Excellence, 2014,Ruther et al., 2014). 
Nicotine replacement therapy is used widely and evidence from clinical practice 
shows that it is also suitable for acute phase patients. Among SMI patients, 
bupropion and varenicline possess strong scientific evidence as pharmacological 
supports to smoking cessation, unlike nicotine replacement therapy (Tsoi et al., 
2013,Roberts et al., 2016). No placebo controlled studies and only few combination 
nicotine replacement therapy (short- plus long-acting formula combined) studies 
have been conducted in patients with SMI (Tidey and Miller, 2015), although 
combination nicotine replacement therapy is shown to be as efficient as varenicline 
in non-SMI samples (Cahill et al., 2013). Nevertheless, one must keep in mind that 
the evidence coming from drug trials with strict exclusion criteria may not always be 
universally generalizable to clinical practice.  
When a patient following psychopharmacological treatment stops smoking or 
smokes tobacco notably less than before, the altered drug metabolism due to 
decreased induction of CYP1A2 enzyme in the liver is important to take into account 
and the dosing of the medication assessed (Rouhos and Raaska, 2012). In particular, 
clozapine blood levels may rise notably due to the lost induction of liver metabolism 
by smoking, and it may lead to worsening of clozapine-related side effects, e.g. risk 
for epileptic seizures (Rouhos and Raaska, 2012). Bupropion increases seizure risk 
as well, and it has also several other potential drug interactions.  
Treatment of concomitant substance misuse and schizophrenia (patients with 
dual diagnosis), according to the Finnish Current Care guidelines for schizophrenia, 
should be integrated. The recommended psychosocial treatments are motivational 
interviewing alone or in combination with cognitive behavioural therapy or 
psychoeducation (The Finnish Medical Society Duodecim and the Finnish 
Psychiatric Association, 2015).  
2.5.5 INTERVENTIONS FOR PHYSICAL ACTIVITY 
Physical inactivity is a major global health problem (Lee et al., 2012). Sedentariness 
and low aerobic fitness have been shown to associate with MetS and higher BMI in 
individuals with schizophrenia (Vancampfort et al., 2012b,Nyboe and Lund, 2013), 
call for action to enhance physical activity in this population. A meta-analysis of 
physical activity RCTs in patients with SMI established a small effect size of 
interventions on body composition, while the effect size on depressive and psychotic 
symptoms was large (Rosenbaum et al., 2014). Accordingly, recent meta-analyses on 
physical exercise in individuals with schizophrenia demonstrated medium effect 
sizes for improvements in social cognition and vigilance, and a small but clinically 
significant effect size for cardiorespiratory fitness (Firth et al., 2016, Vancampfort et 
al., 2015c). 
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The authorities in the field of physical activity research in SMI have pointed out 
some methodological issues across the previous studies to be considered when 
designing future trials (e.g. involvement of exercise professionals in the research 
groups is vital) (Rosenbaum et al., 2015). Aiming to reduce sedentary behaviour and 
increase basic low level physical activity by e.g. walking, may be an achievable and 
realistic intervention, although it has not been studied in the SMI population 
(Vancampfort et al., 2015b). The encouraging evidence of the positive impact of 
reduced sitting to physical health from general population studies could serve as a 
reference. Interestingly, a recent meta-analysis of non-adherence (dropouts) of 
individuals with schizophrenia participating in physical activity RCTs emphazised 
the importance of qualified professionals delivering the programmes, and inclusion 
of motivational aspects and continuous supervision in the interventions 
(Vancampfort et al., 2016). Physiotherapists and physical activity instructors should 
become a part of multidisciplinary teams in the treatment of schizophrenia. 
2.6 SUMMARY OF THE LITERATURE 
Schizophrenia is a severe psychiatric illness that affects about 1% of the population. 
Life expectancy in schizophrenia is shortened, mostly due to premature deaths from 
somatic illnesses. Almost all diseases studied so far are more prevalent in 
schizophrenia compared to the general population. The aetiology of somatic 
comorbidity in schizophrenia is multifactorial. Risk factors range from genetic 
factors, symptoms of the psychiatric illness itself, medications used in the treatment, 
socioeconomic disadvantages and unhealthy lifestyle, to the healthcare system level 
barriers encountered by this patient population. However, several evidence-based 
interventions exist for the treatment of risk factors, such as smoking, obesity and 
physical inactivity, highly prevalent among individuals with schizophrenia.  
An extensive amount of literature has been published on somatic comorbidity in 
schizophrenia. Consequently, monitoring and promoting physical health is strongly 
recommended across the guidelines. However, most studies have focused on a 
limited set of physical health problems, and there is shortage of research observing 
all physical healthcare needs that would emerge in a clinical outpatient setting. 
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3 AIMS OF THE STUDY 
The aim of this observational, cross-sectional study was to assess the range of 
physical problems that emerge in a structured health examination performed by a 
GP, and to evaluate some less studied entities in the field of somatic comorbidity in a 
sample of outpatients with schizophrenia.  
 
The specific aims of this thesis were to assess in outpatients with schizophrenia: 
 
1. Physical healthcare needs (Study I) 
 
2. The prevalence of metabolic syndrome and its associated factors      
(Study II) 
 
3. The prevalence of gastrointestinal symptoms and its associated factors 
(Study III) 
 
4. The prevalence of cerumen impaction and its associated factors        
(Study IV) 
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4 SUBJECTS AND METHODS 
4.1 STUDY DESIGN AND SUBJECTS 
In the “Living Conditions and the Physical Health of Outpatients with 
Schizophrenia” study, a comprehensive physical health examination was offered to 
all patients treated in the psychosis outpatient clinic of Kellokoski Hospital. The 
clinic provides treatment to outpatients with schizophrenia spectrum disorders in 
three municipalities (Järvenpää, Mäntsälä and Tuusula). The participation to the 
health examination was voluntary. Patients were able to participate even if they 
refused the use of their information in the study. Laboratory tests, a questionnaire 
and two separate appointments, one with a nurse and the other with a GP, were 
included in the protocol. Each patient treated at the clinic received a letter or 
telephone call as an invitation to the health examination. The health examinations 
took place in Mäntsälä between July 2009 and February 2010, in Tuusula between 
February 2010 and September 2011 and in Järvenpää between November 2011 and 
December 2013.    
Figure 1. Flow-chart of the study. 
  1 excluded due to not having a schizophrenia spectrum disorder 
2 one participant refused the laboratory tests but attended otherwise, and was included 
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4.2 MEASURES 
The contents of the health examinations are listed in Table 9. Most questions, 
measurements and assessments in the protocol have been previously used in large 
general population studies conducted by the National Institute for Health and 
Welfare (Health 2000 Study, Health Behaviour and Health among the Finnish Adult 
Population Study). Ratings used in the current study were made according to 
established scales. Some questions and procedures were added to the protocol based 
on author´s clinical experience (e.g. concerning self-weighing, constipation, cerumen 
impaction).  
 
Table 9. Contents of the health examinations. 
  
Questionnaire Demographics
1 
Activities of Daily Living (Katz et al., 1963, modified)/ Instrumental Activities of 
Daily Living (Lawton and Brody, 1969, modified)/ Social Cognition (as in Viertiö 
et al., 2012) 
Perceived physical condition, difficulties in moving, vision and memory1 
Problems concerning accommodation facilities1 
Physical activity (Gothenburg Scale, Wilhelmsen et al., 1972) 
Eating Habits (Healthy Eating Habits, Helakorpi et al., 2011)  
Smoking (Kestilä et al., 2006) 
Alcohol Consumption (Alcohol Use Disorders Identification Test-C, Bush et al., 
1998) 
Dental care habits2/ needs 
Preferences in help-seeking concerning physical issues 
Physical health services use 1,2 
Weight and height1, weighing scale at home 
Attitudes towards Neuroleptic Treatment Scale(Kampman et al., 2000)  
Visit to 
 the Nurse 
Current medication use1 
Symptoms (cough1, shortness of breath1, angina1, constipation) 
Verbal fluency test1  
Assessment of difficulties in speaking and understanding1 
Global Assessment of Functioning (American Psychiataric Association, 1994) 
Brief Psychiatric Rating Scale, Scale for the Assessment of Negative 
Symptoms (Ventura et al., 1993, Andreasen, 1989) 
Health of the Nation Outcome Scales (Wing et al., 1998)  
Barnes Akathisia Rating Scale (Barnes, 1989) 
Measurements1 (weight, height, waist, hip and arm circumference, blood 
pressure, near and distant visual acuity) 
Laboratory 
tests 
Fasting blood samples: complete blood count, sodium, potassium, ionized 
calcium, creatinine, glucose, total and high and low density cholesterol, 
triglycerides, glutamyltransferase, thyroid stimulating hormone, 25-
hydroxyvitamin D, electrocardiogram. DNA-sample 
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Visit to  
the GP 
Assessment of primary and specialized care medical records from previous 2 
years  
Current medication use (control)  
Previously diagnosed illnesses (cardiovascular, respiratory, type 2 diabetes, 
hypothyreosis, hyperlipidaemia) 1 
Systematic coronary risk evaluation test SCORE (European Society of 
Cardiology, 2012)  
Medical history of symptoms affecting daily life1  
Structured medical examination1, additional examinations if needed  
Abnormal Involuntary Movement Scale (Guy, 1976) 
Simpson-Angus Scale(Simpson and Angus, 1970) 
Observed difficulties in moving1 
Feedback on tests, physical health status and cardiovascular risk factors 
Interventions (health promotion, medication change, referrals to further 
examinations and monitoring) 
Written summary included in psychiatric records and mailed to the patient and 
his/her general practitioner 
 
Measurement adopted from 1Health 2000 Study (Heistaro, 2008) and 2Health Behaviour and 
Health among the Finnish Adult Population Study(Männistö et al., 2010). Measurements without 
superscript are explained thoroughly in the text                   
In italics: measurements not reported in the thesis or in the articles  
4.2.1 QUESTIONNAIRE  
 
Sociodemographic variables  
 
The following sociodemographic items were included in the self-report 
questionnaire: marital, household and occupational status, basic and secondary 
education. From the sociodemographic variables, information on age, gender, 
employment and living conditions were used in the analyses. Age was used as a 
continuous variable in the analyses. Patients´ occupational status was categorized 
into 1) employed, 2) disability pension and 3) other. Living arrangements (household 
status) were classified as 1) living alone, 2) living with family and 3) living in 
sheltered housing.  
 
Everyday functioning 
 
Difficulties in patients’ everyday functioning were assessed by questions modified 
from those developed by Katz et al. (Katz et al., 1963) and Lawton and Brody 
(Lawton and Brody, 1969). These questions have been used in Finnish general 
population studies as measures of functional capacity (The Finnish National Institute 
for Health and Welfare, 2016). The difficulties were grouped into those related to 
activities of daily living (ADL), instrumental activities of daily living (IADL) and 
social functioning, as in Viertiö et al. (Viertiö et al., 2012). These questions were 
originally used in the Health 2000 Study to assess functional limitations in the PIF 
Study(Viertiö et al., 2012). Patients rated their possible perceived limitations 
concerning 1) getting in and out of bed, dressing, eating, bathing and using the toilet 
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(ADL), 2) shopping, cooking, laundering and heavy cleaning (IADL), and 3) using 
the phone, taking care of matters together with other people, communicating with 
strangers and handling matters in public offices (social functioning). The rating scale 
included four alternatives: no difficulties, minor difficulties, major difficulties and 
total inability to perform a task in question. For statistical analyses, categorical 
variables were formed: if a patient reported any problems or inability to perform 
aforementioned tasks, he/she was considered to have ADL/IADL/ social functioning 
difficulty. 
 
Physical activity, diet, smoking and alcohol consumption 
 
Patients´ physical activity was recorded by so-called Gothenburg scale by asking: 
“How much do you exercise and strain yourself physically in your leisure time?” 
(Wilhelmsen et al., 1972). This scale has been used in several Finnish general 
population studies. A patient was to choose from the following options: 1) I mainly 
read, watch television and perform tasks that don´t strain me physically, 2) I walk, 
cycle or otherwise move at least 4 hours per week, 3) I exercise at least 3 hours per 
week, 4) I am involved in competitive sports. A patient was considered sedentary if 
he/she chose the first option, otherwise he/she was classed regularly physically 
active.  
Patients were asked to memorize consumption of several different foods and 
beverages during the previous week. In addition, type of milk, spread on bread and 
bread they normally consumed was asked. Index of healthy food habits was used as 
described in Health Behaviour and Health among the Finnish Adult Population 
survey (Helakorpi et al., 2011). A patient´s eating habits were considered healthy 
when he/she reported at least two of the following three: 1) eats vegetables daily, 2) 
drinks skimmed milk and/or 3) uses soft margarine or low fat spread on bread. 
Patients were asked if they had 1) ever smoked tobacco, 2) had smoked at least 
100 cigarettes, 3) had smoked on daily basis at least for a year and 4) the last time 
when they had smoked. Depending on the answers, the patient was defined as a: 1) 
non-smoker, 2) ex-smoker or 3) daily smoker. Daily smoking was considered if the 
patient had smoked at least 100 cigarettes, had smoked for at least one year and had 
smoked during the day of the interview or the day before (Kestilä et al., 2006).  
Alcohol consumption was inquired using Alcohol Use Disorders Identification 
Test-C (AUDIT-C), asking 1) how often the patients drank alcohol, 2) the amount 
consumed per occasion and 3) how often they consumed ≥6 units of alcohol. 
Alcohol misuse was considered if a male patient scored ≥4 and female ≥3 (Bush et 
al., 1998). These cut-off points are in accordance with international 
recommendations but are lower than those commonly used in Finland (Kaarne et al., 
2010). AUDIT-C has been validated in primary care (Bradley et al., 2007) and in a 
population with symptoms of depression (Levola and Aalto, 2015). 
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Other questions  
 
Patients were asked if they had visited a GP or a dentist during the previous 12 
months. In addition, patients were asked if they had a weighing scale at home, i.e. 
the equipment used for self-weighing. 
4.2.2 VISIT TO THE NURSE 
Registered psychiatric nurses at the clinic were trained by fieldwork coordinator 
Noora Ristiluoma from the National Institute for Health and Welfare to perform the 
anthropometric measurements according to European Health Examination Survey 
guidelines (Tolonen, 2013), and by Professor Jaana Suvisaari for Health of the 
Nation Outcome Scales (HoNOS) interview and scoring (Wing et al., 1998). Global 
Assessment of Functioning (GAF) scale had been used at the clinic for many years 
and the nurses had received previous training for it(American Psychiatric 
Association, 1994). 
 
Interview 
 
Patients’ current use of medication for psychiatric and physical illnesses was 
inquired by the nurses and coded according to the Anatomical Therapeutic Chemical 
classification system (ATC)  (WHO Collaborating Centre for Drug Statistics 
Methodology, 2009). Respiratory and cardiac symptoms were asked in a structured 
manner in terms of 1) daily coughing and production of sputum while coughing, 2) 
shortness of breath and 3) symptoms of angina (Heistaro, 2008). Symptoms of 
constipation were coded separately by asking if a patient usually defecates 1) at least 
three times a week or 2) twice a week or more seldom. 
 
Measurements 
 
Height was measured by a SECA wall mounted stadiometer with an accuracy of 0.5 
centimetres. Body weight was measured by SECA scale with an accuracy of 100 
grams. Waist circumference was measured using a tailor’s measuring tape halfway 
between the iliac crest and the lowest rib at the end of expiration with an accuracy of 
0.5 centimetres. Blood pressure was measured from the right arm in a sitting position 
three times consecutively with an automatic Omron iC-10 blood pressure monitor. 
The mean of the three measurements was used in the analysis, except in a few cases 
where only one blood pressure measurement was available. Binocular near and 
distant visual acuity were measured with vision charts, the nurses asked the patients 
to wear spectacles during the measurement if they were normally used. 
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Psychiatric diagnoses and ratings 
 
Participants’ psychiatric diagnoses were clinical and made by the treating 
psychiatrists at the clinic or at the hospital according to routine clinical procedures. 
The chief psychiatrist of the clinic, Eila Sailas M.D., reassessed diagnoses of 
unspecified non-organic psychosis (F29).  
GAF is the fifth dimension of the multiaxial assessment model of mental 
disorders in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(American Psychiatric Association, 1994). It is commonly used in clinical practice in 
evaluating patients’ functional status. GAF scale measures psychological, social and 
occupational (but not physical) functioning of a person by a scale from 1-10 
(“persistent danger of harming self or others or persistent inability to maintain 
personal hygiene or person has made a serious attempt at suicide”) to 91-100 
(“person has no problems or has superior functioning in several areas or is admired 
and sought after by others due to positive qualities”). 
Health of the Nation Outcome Scales (HoNOS) is widely used in psychiatric 
settings to measure the severity of problems a person has due to psychiatric illness 
and the gained treatment outcomes (Wing et al., 1998). It was developed by the 
British Royal College of Psychiatrists. HoNOS contains 12 items measuring four 
dimensions of mental health and social functioning: behaviour, impairment, 
symptoms and social functioning. These items are scored from 0 (no problems) to 4 
(severe to very severe problems). The rating is based on all information available 
from the patient over the past month. 
4.2.3 LABORATORY TESTS  
Patients were asked to fast overnight. Fasting blood samples were taken and 
analysed at the Laboratory of Hospital District of Helsinki and Uusimaa. Laboratory 
tests consisted of total blood count, sodium, potassium, ionized calcium, creatinine, 
glucose, total and high and low density cholesterol, triglycerides, 
glutamyltransferase, thyroid stimulating hormone and 25-hydroxyvitamin D. In 
addition, an electrocardiogram (ECG) was registered.  
4.2.4 VISIT TO THE GENERAL PRACTITIONER 
The structure of the physical examination was adapted from the Health 2000 Study. 
Former fieldwork physician Arja Laitinen, M.D., Ph.D., of the National Institute for 
Health and Welfare introduced the GP (the author) to the methodology (Heistaro, 
2008). 
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Medical history taking 
 
Prior to the appointment, the GP assessed the patient’s primary and specialized care 
medical records from two separate databases from the previous 2 years.  
The GP went through the previously filled questionnaire with the patient at the 
beginning of the appointment, and rechecked current medication use. The medical 
history was then taken by inquiring if a patient had symptoms that affected his/her 
daily life. Symptoms were afterwards coded according to the The International 
Classification of Primary Care, 2nd edition (ICPC-2) (Table 10) (WONCA, 2005). 
ICPC-2 is a body system based classification used mainly in Europe and Australia to 
code general practice patient data. It is divided into 17 chapters based on body 
location of the problem a patient presents. Unlike the ICD system, ICPC also 
includes health concerns and symptoms that cannot be defined as accurate diagnoses. 
For example, digestive problems include symptoms such as dyspepsia, constipation 
and nausea; musculoskeletal mainly painful symptoms in the body; and neurological 
problems include symptoms such as headache, dizziness and tingling. 
Table 10. ICPC-2 Classification of symptoms and complaints. 
ICPC-2 Chapter 
A General and Unspecified 
B Blood, Blood Forming Organs and Immune Mechanism 
D Digestive 
F Eye 
H Ear 
K Cardiovascular 
L Musculoskeletal 
N Neurological 
P Psychological 
R Respiratory 
S Skin 
T Endocrine/ Metabolic and Nutritional 
U Urological 
W Pregnancy, Childbearing, Family Planning 
X Female Genital 
Y Male Genital 
Z Social Problems 
ICPC-2 (The International Classification of Primary Care, 2nd edition) 
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Physical examination 
 
The physical examination was semi-structured. It included the following elements in 
all patients: the basic assessment of the mouth, an otoscopy of the ear canals, the 
auscultation of the heart and lungs, the palpation of the abdomen. In addition, a 
visual examination of the skin on the head, upper limbs and upper body was done 
when the patient took off his/her shirt for the auscultation. In case the patient had 
additional health problems, the GP focused the examination as needed.  
 
 
Outcomes of the health examination 
 
The GP concluded appointments by discussing the findings of the measurements, 
laboratory tests and the clinical examination with the patient. When needed, lifestyle 
counselling was given according to the principles of motivational interviewing, 
when appropriate(Miller and Rose, 2009). A written summary of the health check 
was mailed to the patient and to his/her own GP with the patient’s permission, and 
the summary was included in the patient’s psychiatric medical records. 
4.2.5 INTERVENTIONS (I)  
Medical interventions included modification of somatic medication, referrals to 
consultations or to further treatment with the patient’s GP or specialists, or, e.g. to a 
physiotherapist or dietitian, and further examinations, such as laboratory tests or 
radiological examinations. Due to the diversity of the interventions in the health 
examinations, a need for a specific form to collect the data concerning them was 
evident. See Appendix I for the Interventions coding form (in Finnish).   
Afterwards, the medical interventions were classified into 12 categories 
according to ICD-10 main chapters, with the exception of three interventions (blood 
glucose homeostasis, dental interventions and vitamin D supplementation), which 
were so common that they were assessed separately. See Appendix II for the 
Interventions recommended in the clinical assessment according to the disease 
category. The need for vitamin D supplementation was based on low serum 25-
hydroxyvitamin D level. 
4.2.6 METABOLIC SYNDROME (II) 
The presence of MetS was defined according to AHA/NHLBI and IDF criteria 
(Table 5). Prevalence of MetS and its components were calculated. Age, gender, 
living arrangements, eating habits, physical activity, daily smoking, clozapine and 
olanzapine use, and HoNOS symptom score were chosen as potential variables 
associated with MetS risk. Older age, unhealthy lifestyle and AP treatment have 
been previously shown to associate with MetS. However, possible associations of 
living arrangements (as a proxy for real-life functioning) and psychiatric symptom 
severity to MetS have not been established. Concerning current AP medication, four 
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binary variables were formed: 1) clozapine use, 2) olanzapine use, 3) SGA use other 
than clozapine and olanzapine, 4) FGA use. The four variables were not mutually 
exclusive since several patients had AP polypharmacy. When physical activity and 
clozapine use were found to be associated with MetS, it was further analysed which 
factors were associated with physical activity. In addition, differences in the 
components of MetS in association with clozapine were analysed. The same 
variables as in the MetS analysis were used in these models.  
4.2.7 GASTROINTESTINAL SYMPTOMS (III) 
In this study constipation was defined as having 1) less than three defecations per 
week, 2) regular medication use for constipation or 3) constipation diagnosed at the 
GP’s examination requiring a new drug prescription. Dyspepsia was defined as 
either 1) having regular medication for dyspepsia or 2) dyspepsia being diagnosed at 
the GP’s examination requiring a new drug prescription. 
Based on previous research, the following variables were considered as potential 
risk factors for constipation and dyspepsia: female gender, increasing age, obesity, 
sedentary lifestyle, smoking, alcohol misuse, living conditions, diagnosis of 
schizophrenia, use of paracetamol, use of NSAIDs, AP medications (especially 
clozapine), antidepressive medication, mood stabilizing antiepileptics, diabetes and 
non-diabetes endocrinological medication.  
Additionally, it was investigated how often patients with constipation or 
dyspepsia had reported gastrointestinal symptoms affecting their daily life and 
whether constipation or dyspepsia were associated with abnormal laboratory values. 
4.2.8 CERUMEN IMPACTION (IV) 
Cerumen impaction was defined as follows: occlusion of the ear canal causing 
symptoms or preventing the visual assessment of the tympanic membrane. The 
prevalence of cerumen impaction was calculated. Age, gender, GAF score and living 
arrangements (alone or with family vs. sheltered housing) were chosen variables to 
test the predictors of cerumen impaction, based on previous research suggesting that 
functional limitations/disability and living in a nursing home are risk factors for 
cerumen impaction (Mahoney, 1993,Crandell and Roeser, 1993). 
4.3 STATISTICAL METHODS 
In all studies and the thesis the prevalence of conditions have been calculated as 
proportions. Means are given with standard deviations (SD). In Study IV the sample 
consisted of 61 patients (Mäntsälä subsample), in I and III of 275 patients, and in II 
of 276 patients. There was one patient who refused to take part in the GP´s 
examination, but the analysis of MetS (II) could be conducted based on the 
information available from the questionnaire and visit to the nurse.  
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Differences between groups considering categorical variables were tested using 
chi-square test, and with Fisher´s exact test, when the expected frequency in any of 
the cells in a 2x2 table was less than five. Differences between normally distributed 
continuous variables were tested using t-test, or with Mann-Whitney U test for non-
normally distributed variables. To investigate the independent associations between 
selected variables and the manifestation of an outcome, odds ratios (OR) were 
calculated using logistic regression. The ORs are given with 95% confidence 
intervals (CI).  
Two-tailed p-values less than 0.05 were considered statistically significant. 
Statistical analyses were performed with SAS software, version 9.3. 
4.3.1 STUDY I 
The prevalence of patients reporting symptoms affecting daily life and needing 
interventions was calculated. Differences in prevalence of clinical variables, 
patients’ complaints and frequency of interventions in men and women were 
compaired using t-test for continuous, and chi-square or Fisher’s exact test for 
categorical variables. 
Logistic regression was used to analyse whether sociodemographic factors, 
lifestyle, functional limitations, factors related to psychiatric disorder or healthcare 
use predicted the need for interventions across the disease categories.  
Sociodemographic variables in the model were age, gender and living 
arrangements; lifestyle variables were smoking, alcohol misuse, physical activity 
and obesity; functional limitations were perceived problems in ADL, IADL and 
social functioning; psychiatric disorder-related variables were schizophrenia as 
opposed to other schizophrenia spectrum disorders and clozapine use; healthcare-
related variables were visits to GP in previous 12 months and visits to dentist for 
dental diseases. 
4.3.2 STUDY II 
The prevalence of MetS and its components were calculated as percentages. The 
means of the components were calculated and given with standard deviations. The 
differences between gender and MetS, and the existence of MetS components were 
tested using chi-square test and with t-test for means of the measured variables. 
Satterthwaite correction was used in t-test if the groups had unequal variances. 
Odds ratios for variables independently associated with MetS were calculated 
using logistic regression, first in bivariate analysis and then including all variables in 
the model at the same time. In addition, ORs of clozapine use for different 
components of MetS, and of factors predicting self-reported physical activity were 
calculated. The variables tested in the regression models of MetS and clozapine use 
were gender, age, living arrangements, healthy eating habits, regular physical 
activity, daily smoking, clozapine use, olanzapine use and HoNOS symptom score. 
The aforementioned variables except for physical activity were tested in the model 
of predictors of physical activity.  
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4.3.3 STUDY III 
The prevalence of gastrointestinal symptoms constipation and dyspepsia, and the 
individual components of the definitions used to identify them, were calculated. 
Constipation and dyspepsia were analysed separately. In patients with and without 
these conditions, the differences in the sociodemographic (gender, age and living 
conditions), lifestyle (regular physical activity, daily smoking, alcohol misuse) and 
clinical (schizophrenia diagnosis, SGA medications separately, FGA medication as a 
group, mood stabilizing antiepileptics, antidepressive medications, NSAIDs, 
endocrinological medications, diabetes medication, paracetamol use, obesity) 
variables were compared using chi-square or Fisher´s exact test for categorical 
variables, and t-test for continuous variables. Variables that showed significant 
association with gastrointestinal symptoms in previously mentioned analyses were 
entered into logistic regression to investigate which factors were independently 
associated with the symptoms. 
When comparing the median values of laboratory measurements in patients with 
and without constipation or dyspepsia, Mann-Whitney test was used because of the 
non-normal distribution of laboratory values. General linear models were used to test 
the associations between gastrointestinal symptoms and the laboratory results in 
which significant difference was found in Mann-Whitney test. 
4.3.4 STUDY IV 
Prevalence of cerumen impaction was calculated as percentages from the Mäntsälä 
subsample. In patients with and without cerumen impaction the differences in mean 
age and mean GAF scores were compared using t-test, and the differences in gender 
distribution and living arrangements using chi-square test. Logistic regression with 
backward selection was used to investigate whether the aforementioned variables 
predicted cerumen impaction.  
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4.4 ETHICAL QUESTIONS 
The ethics committee of the Helsinki and Uusimaa Hospital District approved the 
study plan (diary no. 387/13/03/03/2008) and the Hyvinkää Hospital Area also gave 
approval for the study. 
The participants gave their written informed consent after having been given a 
complete description of the study by the nurses. The patient could attend the health 
examination even if he/she refused to take part in the study. The patients benefited 
from the study by receiving 1) a comprehensive summary of their current somatic 
health status and cardiovascular risk, 2) new treatments for somatic conditions, 3) 
referrals to further examinations and treatments, 4) recommendations for monitoring 
and 5) face-to-face lifestyle counselling at the GP´s appointment. The summary of  
the health examination was sent by mail, as a reminder, to the patients. The only 
downside of taking part in the study was the momentary pain caused by the blood 
testing. However, 41.7% of the participants were able to give the extra blood 
samples as a part of the monthly laboratory testing for clozapine.  
Certain ethical issues in screening studies are to be addressed: participants should 
not be screened and left without interventions if a need (e.g. further examinations, 
treatment or counselling) occurs. According to the Declaration of Helsinki, 
“physicians who combine medical research with medical care should involve their 
patients in research only to the extent that this is justified by its potential preventive, 
diagnostic or therapeutic value…” (World Medical Association, 2013). This study, 
instead of limiting itself to screening and collecting data, offered the aforementioned 
interventions and, to the author’s understanding, has fulfilled the demands of good 
ethical research practice in that sense. 
4.4.1 PERSONAL INVOLVEMENT 
The preliminary idea for this study arose from the observations of patients´ somatic 
multimorbidity I made as a physician in the psychosis rehabilitation ward of 
Kellokoski Hospital. I planned the study protocol with the members of the study 
group. I wrote the study plan, prepared the materials (examination forms and letters) 
and applied for the permissions. I organized and took part in the training of the study 
nurses. I executed the health examinations. I participated in the design and execution 
of statistical analyses, while Professor Jaana Suvisaari carried the main 
responsibility. I was the first author in three articles (submitted I, and II, IV) and the 
second author in the article III.  
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5 RESULTS 
5.1 CHARACTERISTICS OF THE PARTICIPANTS 
409 patients with schizophrenia spectrum disorders were invited to take part in the 
study and 276 (67.5%) participated. Three patients with non-F20-F29 diagnoses took 
part in the health examinations but were excluded from the analyses. One participant 
refused to go to the laboratory but attended the GP´s appointment and was included. 
One participant returned the questionnaire and participated in the nurse’s assessment 
and laboratory examinations but declined the GP’s appointment. Therefore, the 
number of participants in Studies I and III was 275. Table 11 displays characteristics 
of the participants. 
The mean age of the participants was 44.9 years, and 55.1% were men. In the 
sample women were older. Of the participants, 19.6% lived in sheltered housing, 
32.3% with family and 48.2% alone. Most of the participants (84.4%) were on a 
disability pension. 61 (22.1%) of the participants were from Mäntsälä, 79 (28.6%) 
from Tuusula and 136 (49.3%) from Järvenpää. Of the participants, 190 (68.8%) 
were diagnosed with schizophrenia, 49 (17.8%) with schizoaffective disorder and 37 
(13.4%) with other schizophrenia spectrum disorders. Hereafter, separate diagnoses 
of schizophrenia spectrum disorders are referred to as “schizophrenia”.  
There was no data regarding the non-participants, except for their age, gender 
and the municipality they lived in. There was no significant gender difference 
between participants (55.3% male) and non-participants (59.1% male) (χ2=0.55, 
p=0.46). There was also no significant age difference between participants (mean 
45.0, SD 12.6 years) and non-participants (mean 43.6, SD 13.3 years) (t-test 0.99, 
p=0.32). Participation rates in the three municipalities were 71.8% in Mäntsälä, 
70.7% in Järvenpää and 58.1% in Tuusula. 
 Difficulties in everyday functioning were common. Almost two-thirds reported 
having difficulties in social functioning, one third in ADL and almost three out of 
four in IADL. For example, 132 (47.8%) of the participants reported having 
problems in communicating with strangers, 41 (14.9%) in washing themselves and 
108 (39.1%) in cooking. Women had more problems in ADL, whereas men had 
more problems in social functioning domains. 
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Table 11. Sample characteristics. 
Variable Participants (n=276) 
Age, (years), mean (SD) 44.9 (12.6) 
Male gender, n (%)  152  (55.1) 
Living arrangements  
Living alone, n (%) 133  (48.2) 
Living with family, n (%) 89    (32.3) 
Living in sheltered housing, n (%) 54    (19.6) 
Current employment   
Employed, n (%) 25    (9.0)  
Disablility pension, n (%) 233  (84.4) 
Other1, n (%) 18    (6.5) 
Functioning2  
GAF, mean (SD) 56.1 (12.6) 
ADL difficulties, n (%) 88    (31.9) 
IADL difficulties, n (%) 198  (71.7) 
Difficulties in social functioning, n (%) 175  (63.4) 
 
GAF, Global Assessment of Functioning (American Psychiatric Association, 1994); ADL, 
Activities of Daily Living modified from(Katz et al., 1963); IADL, Instrumental Activities of Daily 
Living modified from(Lawton and Brody, 1969). Social functioning as in(Viertiö et al., 2012)  
1= participants reporting being unemployed, students, taking care of children or other family 
members, on sick leave, or on sheltered work with no information on disability pension status 
2= ADL/IADL/social functioning difficulty was considered when the participant reported any 
problems or inability to perform the tasks in question 
 
Table 12 shows the physical health indicators of the participants. Of the participants, 
114 (41.3%) reported having a sedentary lifestyle, while 40 (14.5%) engaged in 
exercise 3 hours or more per week. 122 (44.2%) reported being physically active (by 
walking, cycling or otherwise moving) at least 4 hours per week. Daily smoking 
(OR=0.57, 95%CI 0.34–0.95, p=0.03) and living in sheltered housing (OR=0.48, 
95%CI 0.24–0.95, p=0.04) were associated with lower odds of being physically 
active. Of the participants, 38.4% were current smokers, while 78 (28.3%) reported 
not having smoked during their lifetime. The mean BMI in the sample was 30.2 
ranging from 17.8 to 61.8. Women (mean BMI 32.0, SD 7.6) had higher BMI than 
men (mean BMI 28.8, SD 5.6) (t-test –3.97, p<0.0001). Of the participants, 212 
(76.8%) had a weighing scale at home. 
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Table 12. Physical health indicators. 
Variable Participants (n=276) 
Regular physical activity, n (%) 162 (58.7) 
Daily smoking1, n (%) 106 (38.4) 
Body Mass Index2, mean (SD) 30.2 (6.7) 
 
1Information missing from 1 participant. 2Information missing from 3 participants 
 
Of the participants, 121 (43.8%) reported no alcohol use, whereas 76 (27.5%) scored 
for alcohol misuse in AUDIT-C. Use of illegal drugs was not inquired in the 
questionnaire but a few participants reported cannabis use in the health examination. 
One participant was on opiate replacement therapy. 
Table 13 shows the psychiatric medications of the participants. The most 
commonly used AP drug was clozapine, 41.7% used it. Polypharmacy with more 
than one AP compound was relatively common. Ten participants (3.6%) didn´t use 
any antipsychotic medication.  
 
Table 13. Psychiatric medications the participants were using. 
Medication 
  
ATC code Participants (n=266) 
Clozapine 
 
N05AH02 115  (41.7%) 
Second-generation    
antipsychotics other than 
clozapine 
N05AE03, N05AE04 
N05AH04, N05AX08 
N05AX12, N05AL05 
153 (55.4%) 
 
 
  
First-generation 
antipsychotics  
N05AA01, N05AA02 N05AB02, 
N05AB03 N05AB04, N05AB10 
N05AC01, N05AD01 N05AD03, 
N05AF03 N05AF01, N05AF05 
N05AL01 
78  (28.3%) 
Antidepressive medication  N06A group  89   (32.2%) 
Antiepileptic or mood 
stabilizing medication 
N03 group 49   (17.8%) 
Lithium N05AN01 14    (5.1%) 
Anxiolytics  
 
N05BA group  105  (38.0%)
  
Hypnotics and sedatives  N05C group  71    (25.7%) 
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5.2 SOMATIC MEDICATIONS (UNPUBLISHED DATA) 
Participants commonly used medications for somatic illness. The mean number of 
somatic medications was 3.3 (SD 2.69, min 0-max 13). Of the participants, only 38 
(13.8%) had no somatic medication.  
The most commonly used medications are shown in Figure 2. Beta-blockers were 
the most common somatic drugs, one participant out of three used them. 27.2% of 
the participants used lipid lowering medication, 26.1% analgesics, 21.4% 
antihypertensives, 19.6% medication for obstructive airway diseases, 13.4% 
antidiabetics and 12.3% medication for hypothyroidism. 29.0% of the patients used 
vitamins.  
 
 
Figure 2. Somatic medications, which >10% of the participants were using, divided into ATC-
groups. 
A02 (drugs for acid-related disorders, i.e. 
dyspepsia) 
A06 (drugs for constipation) 
A10 (drugs used in diabetes) 
A11 (vitamins) 
A12A (calcium)  
B01 (antithrombotic agents) 
C03 (diuretics)  
C7 (beta-blocking agents) 
C08 (calcium channel blockers),  
C09 (agents acting on the renin-angiotensin 
system) 
C10 (lipid modifying agents) 
G (genitourinary system and sex hormones) 
H03 (thyroid hormones) 
M01 (anti-inflammatory and antirheumatic 
products) 
N02 (paracetamol) 
R03 (drugs for obstructive airway diseases)  
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5.3 SOMATIC HEALTH SERVICE USE (PARTLY 
UNPUBLISHED DATA) 
Of the participants, 176 (63.8%) reported having visited a GP and 177 (64.1%) a 
dentist during the previous 12 months, whereas 23 (8.3%) of the participants 
reported that the last visit to the dentist was more than 5 years ago. There was no 
gender difference in GP visits, but women reported visiting a dentist more often than 
men within the previous year. 
The participants were also asked when was the last time their blood pressure, 
cholesterol, glucose or waist circumference had been measured (Table 14). Of the 
participants, 69.8% reported having had blood pressure, 59.4% blood cholesterol and 
60.0% glucose measured by a healthcare professional within one year, whereas waist 
circumference had been measured for 22.1% of the participants within a year. 
 
Table 14. When was the last time a healthcare professional measured your?                    
(number of the participants, frequency (n, (%)) (unpublished data). 
 0-12 
months 
ago 
1-5 years 
ago 
>5 years ago Never I don´t 
know 
Blood 
pressure1 
192 (69.8%) 66   (24.0%) 10   (3.6%) 0       (0.0 %) 7     (2.5%) 
Cholesterol 164 (59.4%) 63   (22.9%) 8     (2.9%) 5     (1.8%) 36   (13.0%) 
Glucose1 165 (60.0%) 63   (22.9%) 5     (1.8%) 5     (1.8%) 37   (13.5%) 
 
Waist 
circumference 
61 (22.1%) 48 (17.4%) 16 (5.8%) 81 (29.3%) 70 (25.4%) 
 
1Information missing from 1 participant 
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5.4 SOMATIC SYMPTOMS  
At the GP´s appointment 124 (44.9%) of 275 participants reported any kind of 
somatic symptoms affecting daily life (Figure 3). Of the participants, 80 (29.1%) had 
one, 36 (13.1%) two and 8 (2.9%) three separate somatic symptoms. Coded 
according to ICPC-2, musculoskeletal, digestive and neurological symptoms were 
mentioned most often. Of the participants, 90 (32.7%) reported distressing 
psychological symptoms interfering with daily life.  
 
  
Figure 3. Frequency (n) of the somatic symptoms mentioned affecting daily life according to 
ICPC-2, International Classification of Primary Care, version 2. 
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5.5 NEED FOR HEALTHCARE INTERVENTIONS 
(PARTLY UNPUBLISHED DATA) (I)  
81.1% of the participants received some kind of lifestyle counselling from the GP. 
Half of the participants were advised to lose weight, 42.9% to increase their physical 
activity and one third to stop smoking. Numerous participants received advice for 
several lifestyle issues (Table 15). 
Table 15. Need for lifestyle counselling in 275 participants (unpublished data). 
Target of counselling Frequency (n, (%)) 
Weight loss 141 (51.3%) 
Physical activity 118 (42.9%)  
Smoking  94 (34.2%) 
Hygiene 48 (17.5%) 
Substance use 25 (9.1%) 
Miscellaneous 38 (13.8%) 
Any  223 (81.1%) 
 
Of the participants, 87.6% received interventions from the GP for any somatic 
disease or condition (Table 16). Most commonly the interventions were related to 
CV, dermatological, dental, ophthalmological and gastrointestinal conditions, and 
for altered glucose homeostasis. The participants could receive several interventions 
from one category (e.g. monitoring of blood pressure and titration of 
antihypertensive medication in CV category). The median number of interventions 
from different disease categories per patient was three (25th percentile 2, 75th 
percentile 4, range 0-7). Only 34 (12.4%) participants did not require intervention. 
No gender differences existed in need for interventions across the categories, apart 
from urological and gynaecological diseases. See Appendix II for more detailed 
information on individual interventions within the categories. 
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Table 16. Number of participants with interventions by disease category (n=275). 
Interventions (in order of prevalence) Number of 
participants with 
interventions 
Cardiovascular  
The monitoring of blood pressure, antihypertensive medication (initiation, 
up/down titration, termination), lipid lowering medication, antithrombotic 
medication, other medication, additional examination, consultation with 
cardiologist 
 
 
118 (42.9%) 
Dermatological  
Corticosteroids for topical use, preparations for skin care, antimicrobials 
for topical use, consultation with chiropodist or dermatologist, additional 
examination  78 (28.4%) 
Dental  
Consultation with dentist, preparation for dry mouth, consultation with 
dental hygienist 77 (28.0%) 
Blood glucose homeostasis 
Additional examination, antidiabetic medication, glucose monitoring at 
home 69 (25.1%) 
Ophthalmological   
Consultation with ophthalmologist, consultation with optician, preparations 
for dry eyes 
 
66 (24.0%) 
Gastroenterological  
Laxative, medication for dyspepsia, psyllium fibre, additional examination, 
topical preparation for haemorrhoids 63 (22.9%) 
Ear, nose and throat  
Removal of cerumen impaction, nasal corticosteroid preparation, 
consultation with otorhinolaryngologists, audiometry 49 (17.8%) 
Musculoskeletal  
Analgesics, physiotherapy, additional examination 38 (13.8%) 
Respiratory  
Additional examinations, medication for respiratory diseases, nasal 
emollients, consultation with pulmonologist 33 (12.0%) 
Gynaecological  
Additional examinations, medication for gynaecological diseases, 
consultation with gynaecologist,  15 (5.5%) 
Endocrine  
Medication for hypothyroidism, consultation with endocrinologists 8 (2.9%) 
Vitamin D supplementation  
88 (32.0%) 
Other  
Consultation with haematologist, neurologist, urologist, nephrologist. Mini 
Mental State Examination for the screening of cognitive impairment. 
Medication: varenicline, iron preparation, vitamin B, calcium preparation 13 (4.7%) 
Participants with any intervention  
241 (87.6%) 
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In the logistic regression model, daily smoking (OR=2.33, 95%CI 1.06-5.13, 
p=0.035) and obesity (OR=2.60, 95%CI 1.12-6.05, p=0.026) were the variables 
predicting a need for any intervention. Visiting a GP within 12 months did not 
reduce any type of intervention need. Visiting a dentist within 12 months predicted 
less need for dental intervention.  
Statistically significant predictors associated with intervention needs are 
presented in Table 17. Participants reporting current use of vitamin D were excluded 
from the analysis of need for vitamin D supplementation. There was no difference in 
vitamin D use between participants using clozapine and other APs. 
Ophthalmological interventions were not predicted by any of the chosen variables. 
Gynaecological and endocrine interventions were not analysed separately due to the 
low number. 
Table 17. Predictors of need for intervention by disease category1.  
Intervention 
category 
Predictor of need for 
intervention 
Odds ratio 95%CI, p value 
 
Cardiovascular Obesity  
Older age  
OR=2.61(1.51-4.53), p=0.0006  
OR=1.03 (1.01-1.05), p=0.009 
Dermatological Obesity  
Daily smoking  
OR=2.24 (1.23-4.08), p=0.008  
OR=0.34 (0.18-0.64), p=0.0009 
Dental Regular physical activity 
Visit to the dentist within the 
previous 12 months 
OR=0.51 (0.27-0.93), p=0.029 
OR=0.39 (0.22-0.71), p=0.0019  
Blood glucose 
homeostasis 
Obesity  OR=1.98 (1.06-3.71), p=0.033 
Gastrointestinal Clozapine use  
Female gender  
OR=4.29 (2.06-8.96), p=0.0001  
OR=2.57 (1.23-5.34), p=0.012 
Ear, nose and 
throat 
Living in supported housing  OR=2.38 (1.01-5.58), p=0.015 
Musculoskeletal Older age  OR=1.04 (1.01-1.08), p=0.012 
Respiratory 
diseases 
Daily smoking  OR=6.03 (2.49-14.60), p<0.0001 
Vitamin D 
supplementation 
Clozapine use  OR=0.34 (0.18-0.66), p=0.0015 
 
1All models in the analyses included the following explanatory variables: age, gender, living 
arrangements, daily smoking, alcohol misuse, regular physical activity, obesity, limitations in 
ADL, IADL and in social functioning, diagnosis of schizophrenia (as opposed to other 
schizophrenia spectrum disorders), clozapine use, visits to GP in previous 12 months, and visits 
to dentist in dental diseases 
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5.6 METABOLIC SYNDROME (II) 
Of the participants, 162 (58.7%) had MetS according to the IDF definition and 154 
(55.8%) according to the AHA/NHLBI definition (Table 18). Women were more 
often centrally obese than men (IDF definition: 114 (94.2%) vs. 121 (79.6%), 
χ2=12.0, p<0.001; AHA/NHLBI definition: 97 (80.2%) vs. 84 (55.3%), χ2=18.7, 
p<0.001). Men had higher systolic blood pressure compared to women, but the 
prevalence of the MetS criterion for elevated blood pressure did not differ 
significantly between men and women. No gender differences existed in the total 
prevalence of MetS, in elevated fasting glucose or elevated triglycerides, or in 
clozapine use.  
The logistic regression analysis assessing the risk of MetS diagnosed by IDF 
definition included the following explanatory variables: gender, age, living 
arrangements, healthy eating habits, regular physical activity, daily smoking, 
clozapine use, olanzapine use and HoNOS symptom score. Risk of MetS was 
doubled in patients using clozapine (OR=2.04, 95%CI 1.09-3.82, p=0.03). In 
addition, increasing age increased the risk (OR=1.04, 95%CI 1.01–1.06, p=0.003) 
and self-reported regular physical activity decreased the risk (OR=0.32, 95%CI 0.18-
0.57, p<0.001). No associations between MetS and living arrangements or severity 
of psychiatric symptoms measured by HoNOS symptom scale were found. The risk 
of MetS was associated with the same variables when AHA/NHLBI definition was 
used.  
Table 18. Prevalence of Metabolic Syndrome and its components.  
 n with 
available 
data 
AHA/NHLBI  
n, (%) 
IDF  
n, (%) 
Metabolic syndrome 272 154 (55.8%) 162 (58.7%) 
Abdominal obesity (cm) 
AHA/NHLBI: ≥102 men and ≥88 women, IDF: 
≥94 men and ≥80 women 
273 181 (65.6%) 235  (85.1%) 
Elevated blood pressure (mmHg) 
(≥130/85)  or medication for the condition 
271 157  (56.9%) 157 (56.9%) 
Elevated fasting glucose (mmol/l) 
 (≥5.6) or medication for the condition  
274 193  (69.9%) 193 (69.9%) 
Reduced HDL cholesterol (mmol/l) 
(≥1.03 in men and 1.3 in women) or 
medication for the condition  
274  96   (34.8%) 96   (34.8%) 
Elevated triglycerides (mmol/l) 
(≥1.7) or medication for the condition  
274 106  (38.4%) 106  (38.4%) 
 
AHA/NHLBI, American Heart Association/National Heart, Lung and Blood Institute; IDF, 
International Diabetes Federation 
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Differences in the components of MetS were tested for association with clozapine 
use using the same explanatory variables as in the full MetS model. Clozapine users 
had an almost 3-fold risk for elevated fasting glucose (OR=2.76, 95%CI 1.34–5.59, 
p=0.005) and low high-density lipoproteins (OR=2.80, 95%CI 1.48–5.30, p=0.002), 
and an almost 2.5-fold risk for elevated triglycerides (OR=2.42, 95%CI 1.31–4.47, 
p=0.005), whereas there was no significant association between clozapine use and 
abdominal obesity or elevated blood pressure. 
5.7 GASTROINTESTINAL SYMPTOMS (III) 
Of the participants, 86 (31.3%) had constipation and 65 (23.6%) had dyspepsia. 
Among participants with constipation, the prevalence of dyspepsia was 27.6%, while 
the prevalence of constipation among those with dyspepsia was 36.9%. The 
comorbidity between the two symptoms was not statistically significant (χ2=1.26, 
p=0.26).  
Regarding the prevalence of individual components of the definition used for 
constipation, 31 (11.3%) of all participants reported less than three defecations per 
week, 61 (22.2%) used medication for constipation regularly and 44 (16.0%) 
received a new drug prescription or changes to previous medication for constipation 
at the GP´s visit.  
Of the participants with constipation or dyspepsia, 22.8% (29 out of 127) 
reported gastrointestinal symptoms affecting daily life, compared to 4.1% (6 out of 
148) of the other participants (χ2=21.7, p<0.0001). The frequency of distressing 
gastrointestinal symptoms was similar among participants having both problems 
(25.0%, 6 out of 24), constipation only (22.6%, 14 out of 62) and dyspepsia only 
(22.0%, 9 out of 41). 
Of the participants, 56 (20.4%) used medication for dyspepsia and 13 (4.7%) 
required a new drug prescription or changes to previous medication for dyspepsia at 
the GP´s visit. 25 out of 86 (29.1%) of participants with constipation, and 9 out of 65 
(13.8%) of participants with dyspepsia were new cases diagnosed at the GP´s visit, 
while the others defined to have constipation or dyspepsia were already using 
medication for these symptoms. Of the previously diagnosed ones, 26 out of 61 
(42.6%) participants with constipation and 4 out of 56 (7.1%) with dyspepsia 
required a medication change. 
Older age, living in sheltered housing, diagnosis of schizophrenia, paracetamol 
and clozapine use were significantly associated with a higher prevalence of 
constipation. Quetiapine use, regular physical activity and alcohol misuse were 
associated with lower prevalence of constipation (Table 19). 
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Table 19. Variables associated with constipation. 
 Constipation (n=86) No constipation 
(n=189) 
p value 
Variable 
 
Mean (SD) or frequency 
(n, (%)) 
Mean (SD) or frequency 
(n, (%)) 
 
Age (years) 47.3 (13.2) 43.9 (12.9) 0.038 
Sheltered housing 27 (31.4%) 27  (14.3%) 0.004 
 
Schizophrenia 
diagnosis 
67 (77.9%) 122 (64.6%) 0.027 
Paracetamol use 
 
20 (23.3%) 18 (9.5%) 0.002 
Clozapine use 
 
56 (65.1%) 58 (30.7%) <0.001 
Quetiapine use 
 
6 (7.0%) 32 (16.9%) 0.027 
Regular physical 
activity 
43 (50.0%) 119 (63.0%) 0.043 
Alcohol misuse 
 
17 (19.8%) 59 (31.4%) 0.04 
 
In the logistic regression model, assessing the risk for constipation included the 
following explanatory variables: age, living arrangements, diagnosis of 
schizophrenia, paracetamol use and clozapine use. Older age (OR=1.04, 95%CI 
1.01–1.06, p=0.005), living in sheltered housing (OR=2.49, 95%CI 1.16–5.33, 
p=0.030), clozapine use (OR=5.48, 95%CI 2.75–10.90, p<0.001) and paracetamol 
use (OR=3.07, 95%CI 1.34–7.02, p=0.008) remained significantly associated with 
an increased risk of constipation. 
Women had dyspepsia more often than men. In addition, diabetes medication 
use, NSAID use and obesity were significantly associated with an increased 
prevalence of dyspepsia (Table 20). 
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Table 20. Variables associated with dyspepsia. 
 Dyspepsia (n=65) No dyspepsia (n=210) p value 
Variable 
 
Mean (SD) or 
frequency (n, (%)) 
Mean (SD) or  
frequency (n, (%)) 
 
Sex (n (%) females)) 
 
40 (61.5%) 83 (39.5%) 0.002 
BMI ≥30 39 (60.0%) 
 
91 (44.0%) 0.024 
Diabetes medication 
 
16 (24.6%) 21 (10.0%) 0.003 
NSAID medication 
 
14 (21.5%) 20 (9.5%) 0.010 
 
BMI, Body Mass Index; NSAID, Non-Steroidal Anti-inflammatory Drug 
   
Female gender (OR=2.10, 95%CI 1.15–3.83, p=0.015), diabetes medication use 
(OR=2.42, 95%CI 1.12–5.25, p=0.025) and NSAID medication use (OR=2.47, 
95%CI 1.13–5.39, p=0.023) were associated with a statistically significant increased 
risk for dyspepsia in the logistic regression using gender, diabetes medication use, 
NSAID use and obesity as explanatory variables. 
No associations between abnormal laboratory measurements and constipation or 
dyspepsia were found in the general linear regression analysis. 
5.8 CERUMEN IMPACTION (IV) 
Of the Mäntsälä subsample (n=61), 12 (19.7%) participants were diagnosed with 
cerumen impaction. Males, participants living in sheltered housing and those with 
lower GAF scores had cerumen impaction more often. Living in sheltered housing 
(OR=13.7, 95%CI 3.0-64, p<0.001) significantly predicted diagnosis of cerumen 
impaction in the logistic regression model using age, gender and GAF as other 
potential explanatory variables. 
Of the participants with cerumen impaction 33.3% reported problems in washing 
themselves, compared to 12.2% of participants without cerumen impaction (Fisher`s 
exact test p=0.077). 
In addition, it was studied whether the diagnosis of cerumen impaction was 
predicted by medications with marked anticholinergic properties (amitriptyline, 
haloperidol, levomepromazine, chlorprothixene, zuclopenthixol, olanzapine and 
clozapine). Statistical significance was not reached (p=0.089). The result was similar 
in the logistic regression model using gender, age, living conditions and GAF score 
as other potential explanatory variables. 
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6 DISCUSSION 
6.1 NEED FOR INTERVENTIONS IN HEALTH 
EXAMINATIONS 
This study revealed a large amount of physical healthcare needs in a sample of 
outpatients with schizophrenia invited to a health examination, with a mean age of 
45 years.  
The majority (88%) of the patients were judged to have some kind of need for 
intervention and 81% received lifestyle counselling, most often regarding obesity, 
smoking and sedentariness. The most evident needs for intervention concerned CV, 
dermatological, dental, glucose-related, ophthalmological and gastroenterological 
issues, and vitamin D supplementation. Of the participants, 45% had somatic 
symptoms affecting daily life. Strikingly, visiting a GP within a year did not reduce 
the need for interventions. Compared with the findings from studies conducted over 
30 years ago, the health problems of the current study had similar features (Koranyi, 
1979,Barnes et al., 1983,Maricle et al., 1987,Honig et al., 1989). High rates of 
concurrent physical problems in schizophrenia have also been reported previously in 
studies based on general practice databases (Smith et al., 2013,Truyers et al., 2011).  
The participants of the current study were obese more than twice as often as the 
general population in Finland (Borodulin et al., 2015), a pattern well recognized in 
literature of somatic comorbidity of SMI (Allison et al., 2009,Correll et al., 2014). 
Obesity predicted the need for interventions in general, and specifically for 
cardiovascular and dermatological diseases, as well as interventions concerning 
glucose homeostasis. The increased risk for T2D and CV diseases caused by obesity 
is widely known, and the association between obesity and dermatological diseases 
has also been previously reported (Yosipovitch et al., 2007). Despite the importance 
of weight control when using AP medication, one in four in the sample did not have 
a weighing scale at home. 
Compared to a Finnish general population survey in 2012 with 29% of men and 
19% of women reporting smoking (Jousilahti et al., 2016), smoking was more 
prevalent in the study population (38%). Accordingly, individuals with 
schizophrenia have repeatedly displayed high smoking rates (Partti et al., 2015,Tidey 
and Miller, 2015). In the current study, a strong association existed between smoking 
and the need for respiratory interventions in accordance with the literature (Forey et 
al., 2011,Urrutia et al., 2005). In addition, smoking more than doubled the need for 
any intervention. Similar results were obtained recently from the Northern Finland 
1966 birth cohort, where middle-aged smokers used primary healthcare services 
more often compared to non-smokers (Keto et al., 2017). Promotion of smoking 
cessation, and prevention of smoking as well, should be prioritized for individuals 
with schizophrenia across the healthcare system. Universal methods used in the 
treatment of tobacco dependency (nicotine replacement therapy, medication, 
psychological support) are recommended for patients with SMI as well (Ruther et 
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al., 2014). Interestingly, in the current study one third of the participants reported 
having succeeded in smoking cessation. 
The prevalence of alcohol misuse was relatively low and in line with previous 
literature (Koskinen et al., 2009). Using the culturally proposed AUDIT-C cut-offs 
(men ≥6, women ≥5) (Kaarne et al., 2010) 17.8% of men and 12.2% of women 
scored for alcohol misuse. However, only 9% of the participants received 
counselling from the GP for substance misuse. This may reflect the difficulties of the 
author to interfere with patients´ alcohol misuse. An optional explanation is that the 
participants may have already had ongoing interventions for substance use available 
at the clinic or at Alcoholics Anonymous, and the intervention was omitted because 
of that. 
Clozapine use was associated with over a fourfold increase of gastroenterological 
interventions, mostly concerning constipation and laxative use. In line with this, 
clozapine is a known risk factor for constipation and for severe gastrointestinal 
complications (Shirazi et al., 2016,Nielsen and Meyer, 2012). Interestingly, 
clozapine use was associated with less need for vitamin D supplementation in this 
study, even after adjusting for milk use and excluding the patients using vitamin D 
substitute. There is a possibility that clozapine affects the vitamin D metabolism. 
Rodent studies have shown no effect of AP medications on vitamin D status, 
although vitamin D deficiency may worsen AP-induced glucose and lipid 
disturbances in rats (Dang et al., 2015). In addition, vitamin D deficiency was 
recently associated with MetS in patients with psychosis (Lally et al., 2016). 
Metabolic and CV problems have gained the most attention in the literature and 
treatment guidelines on somatic comorbidity in schizophrenia. The current study 
indicates that these problems constitute just the tip of the iceberg of physical health 
problems among individuals with schizophrenia. 
To date, there is convincing evidence that lifestyle interventions are able to 
reduce cardiometabolic risk factors in SMI patients, but data is lacking whether 
lifestyle interventions or cardiometabolic monitoring reduces the mortality rate 
(Baxter et al., 2016). In a Cochrane review on the monitoring of physical healthcare 
for people with SMI, the researchers were unable to find relevant trials that assess 
monitoring practices (Tosh et al., 2014).  
No effect of health checks for unselected general population cohorts on 
mortality, or CV and cancer morbidity was found in Cochrane researchers´ review 
(Krogsboll et al., 2012). However, most of the trials included in the review were 
conducted more than 30 years ago. A recent Danish controlled trial of population-
based screening and lifestyle interventions tailored for those with increased CV 
disease risk did not show reductions of mortality or CV morbidity in a 10-year 
follow-up (Jorgensen et al., 2014). Evidence on health examinations and 
interventions with hard end points among SMI cohorts are probably impossible to 
obtain, due to the large number of patients needed in such intervention trials and the 
considerable length of the needed follow-up. Hence, generalization of previous 
negative findings in a high-risk population having several obstacles in recognizing 
(e.g. altered pain perception, cognitive deficits) and receiving (e.g. difficulties in 
communication, stigma, poverty) help for their physical problems may be difficult. 
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In addition, reductions in mortality and CV morbidity may seem somewhat limited 
as sole objectives for interventions. Relevant aims of the health examinations could 
also be to reduce multimorbidity by treatment and prevention, and to offer assistance 
in overcoming distressing symptoms to enhance quality of life. Nevertheless, due to 
the large amount of physical health problems and intervention needs found 
previously and in this study, it is plausible to assume that individuals with 
schizophrenia may benefit from health examinations.  
6.2 METABOLIC SYNDROME 
The prevalence of MetS in this study (59%) was higher compared to the 33% 
established in meta-analyses of patients with schizophrenia(Mitchell et al., 
2013,Vancampfort et al., 2015a) and the PIF Study (Suvisaari et al., 2007), but 
similar compared to recent large Australian (Morgan et al., 2014) and British 
(Gardner-Sood et al., 2015) outpatient studies.  
Regarding the separate components of MetS, compared to the most recent review 
of MetS in SMI (Vancampfort et al., 2015a), the participants of the current study 
were more often centrally obese and had more often elevated fasting glucose and 
elevated blood pressure, whereas the rates of elevated triglycerides and reduced 
high-density lipoproteins did not differ. Consistent with Vancampfort et al. (2015a), 
in the current sample increasing age predicted MetS but no gender difference 
existed. However, in the current study women were more often centrally obese and 
had higher BMI compared to men. 
Clozapine is the most efficacious AP drug on the market (McEvoy et al., 
2006,Leucht et al., 2013), but it exhibits the highest risk for MetS of all APs 
(Vancampfort et al., 2015a). Accordingly, the patients in this sample using clozapine 
had a 2-fold risk of MetS. In addition, clozapine use was associated with a 3-fold 
risk for elevated fasting glucose and hypertriglyceridemia, and a 2.5-fold risk for low 
high-density lipoproteins. An established outcome of MetS is T2D, and the 
development of T2D has previously been reported in one third of clozapine users in 
a 10-year follow-up (Henderson et al., 2005). In this sample 12.7% of patients using 
clozapine vs. 14.3% of other APs had antidiabetic medication.  
Participants reporting any kind of physical activity had a lower risk for MetS in 
the current study. Sedentary lifestyle is a risk factor for MetS (Grundy et al., 
2005,Nyboe et al., 2015). Interestingly, most patients in the sample who were 
considered non-sedentary, thus having a lower risk for MetS, were physically active 
by means of walking and cycling instead of exercising. Smoking and living in 
sheltered housing were associated with a sedentary lifestyle, yet there was no 
association between sedentariness and the severity of psychiatric symptoms. An 
association between smoking and sedentariness has been established also previously 
(Chwastiak et al., 2011). The aforementioned finding suggests that an inactive 
lifestyle in sheltered housing was primarily related to a less demanding environment 
(no need/ability to take care of activities outside home) than to more severe 
psychiatric symptoms. In prevention and treatment of MetS enhancing physical 
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activity, even moderately like regular walks, for individuals living in sheltered 
housing is important.  
6.3 GASTROINTESTINAL PROBLEMS 
Gastrointestinal problems were common (31% had constipation and 24% dyspepsia) 
among the participants of the current study. Of the participants who had constipation 
or dyspepsia, 23% considered that these symptoms affected their daily life.  
The prevalence of constipation was higher compared to the prevalence reported 
in European general population samples (17%) and globally (16%) (Peppas et al., 
2008,Suares and Ford, 2011), whereas the prevalence of dyspepsia among the 
participants did not differ from the prevalence of dyspeptic symptoms (22%) 
reported in the meta-analysis from population-based studies (Ford et al., 2015). 
Comparing the prevalence of gastrointestinal problems is somewhat difficult due to 
the variety of definitions used across studies. In this study constipation and 
dyspepsia were defined taking into account patients’ self-reported symptoms, current 
medication use for these conditions and the clinical judgement of the GP, mirroring 
everyday clinical practice.  
Clozapine is an established risk factor for constipation (Correll et al., 2015,De 
Hert et al., 2011c). Compared with the prevalence (31%) and the threefold odds of 
constipation among clozapine users versus the users of other APs in a recent meta-
analysis (Shirazi et al., 2016), among the clozapine users of this study sample the 
prevalence (49%) and the over fivefold odds were even more pronounced. 
The threefold risk of constipation in participants using paracetamol is in line with 
evidence from a single general population survey also examining paracetamol as one 
of the possible risk factors for constipation (Chang et al., 2007). The authors 
speculated that the cause for this association could be the anti-serotonergic effects of 
paracetamol on the gut. Advanced age is a well-known risk factor for constipation 
(Suares and Ford, 2011), whereas living in sheltered housing, to the author’s 
knowledge, has not been previously associated with constipation. 
In the current study, female gender, NSAID and diabetes medication use were 
associated with higher odds of dyspepsia, in accordance with previous literature 
(Ford et al., 2015,Hoffmann et al., 2003,Bouchoucha et al., 2011). Diabetes may 
cause gastrointestinal manifestations by autonomic dysfunction (Bouchoucha et al., 
2011). Nevertheless, when diabetes medication was taken into account in the 
analysis, dyspepsia did not predict higher plasma glucose, pointing to the association 
between medication and dyspepsia more than to one between dyspepsia and 
diabetes. All participants with T2D used metformin, but a few also used other 
diabetes medications. This limited the possibility to examine the effect of diabetes 
medications other than metformin. There is suggestive evidence of the effectiveness 
of NSAIDs for psychotic symptoms (Sommer et al., 2014) and metformin for AP-
induced weight gain (Correll et al., 2013,Siskind et al., 2016). Hence, the balance 
between the wanted and unwanted consequences in prescribing any medication is 
important, and especially crucial in cases of off-label indications. 
Discussion 
82 
Of note is that 43% of participants reporting current medication use for 
constipation were advised to modify the laxative medication, usually to increase the 
dose. Of the participants using medication for dyspepsia, only 7% required a 
medication change based on the information gathered in the examination.  
6.4 CERUMEN IMPACTION 
To the author’s knowledge, previous studies on the prevalence of cerumen impaction 
in schizophrenia do not exist. However, there is evidence that it is common among 
institutionalized geriatric and intellectually impaired patients (Mahoney, 
1993,Crandell and Roeser, 1993). Living in sheltered housing predicted cerumen 
impaction in the current study. A plausible explanation for this phenomenon lays in 
the difficulties in self-care. It seems that individuals needing assistance in daily 
living are at risk of having cerumen impaction.  
Pain is a common symptom caused by cerumen impaction (Roland et al., 2008). 
Another explanation for the high prevalence of cerumen impaction in the sample 
could be the pattern of higher threshold to pain typical in schizophrenia (Stubbs et 
al., 2015b). The participants in the study may not have noticed the pain caused by it, 
and thus have not sought help for the condition.  
Males in our sample had cerumen impaction more often. Accordingly, the effect 
of gender on cerumen impaction has been reported previously in some studies 
(Roland et al., 2008,Burton and Doree, 2009). Dryness of the ear canal due to 
diminished glandular secretion due to advanced age has also been postulated as a 
risk factor (Burton and Doree, 2009). Nevertheless, in this study no effect of age on 
cerumen impaction was found. 
Patients with schizophrenia may have difficulties in noticing and seeking help for 
cerumen impaction that may lead to hearing impairment and difficulties in social 
interaction. The staff in sheltered housing should receive training regarding physical 
health issues, and difficulties in taking care of personal hygiene among residents 
should be considered. An otoscopy should be conducted at least annually especially 
for individuals with schizophrenia with low GAF score and living in sheltered 
housing, and cerumen impaction should be removed when present.  
6.5 CLOZAPINE 
Clozapine use was associated with a marked increased risk for MetS and 
constipation among the participants of the current study. Despite the risk of 
agranulocytosis and metabolic adversities clozapine has, it is widely used in Finland 
(The Finnish Medicines Agency Fimea and Social Insurance Institution, 2015) 
among treatment resistant patients, due to the effectiveness and few extrapyramidal 
side effects. Of the participants, 42% used clozapine. Clozapine is considered the 
most effective AP (Leucht et al., 2013), but it is underused in most countries (Howes 
et al., 2012,Latimer et al., 2013). Consequently, psychiatrists have been strongly 
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recommended to use clozapine more frequently in the treatment of schizophrenia 
(Patel, 2012).  
Clozapine has a wide range of potential side effects that have to be taken into 
account and communicated to the patient. In addition, clozapine treatment requires 
regular monitoring (Cohen et al., 2012). However, awareness of the typical 
adversities of clozapine has been shown to be lacking, even among staff familiar 
with clozapine patients (De Hert et al., 2016). 
Patients using clozapine should be supported to prevent weight gain and 
metabolic adversities by self-weighing, healthy diet and by being physically active 
and smoke free. They should be informed of the propensity of clozapine to cause 
constipation. In addition, constipation should be assessed regularly, either by asking 
direct questions about the frequency and possible difficulties in defecation or by a 
side effect questionnaire, preferably by both means. Constipation has to be treated 
efficiently. In addition, the blood clozapine level monitoring, in case of smoking 
cessation, has to be kept in mind and measured accordingly.  
6.6 STRENGTHS AND LIMITATIONS 
The main strength of the current study is the comprehensive evaluation of the 
outpatients’ overall health by a GP, based on structured clinical examination, 
followed by necessary interventions. To the best of the author’s knowledge, studies 
using a similar method have not been published over the past 30 years (Honig et al., 
1989). The amount of information gathered from the patients covered numerous 
aspects of health: sociodemographic background, health behaviour, use of somatic 
medication and services, somatic and psychiatric symptomology and functional 
status. Measurements were executed in a standardized manner and training for them 
was provided by research personnel from the National Institute for Health and 
Welfare. 
The results of the current study can be considered fairly representative of Finnish 
outpatients with schizophrenia. The study was accessible to all outpatients registered 
at the clinic diagnosed with schizophrenia. The patients came from three different 
municipalities (one urban and two rural), and the participation rate was good. 
Regarding limitations of the study, the major concern is the absence of a healthy 
control group, which makes comparison between participants and the general 
population difficult. Although the prevalence of the most common somatic 
conditions in the Finnish general population are known, e.g. from The Health 2000 
Study (Saarni et al., 2006), the amount of unrecognized health problems is not 
known. Moreover, due to the cross-sectional design of the study it is impossible to 
determine causal relationships: only associations between outcomes and selected 
variables can be evaluated. Because of that, the logistic regression models used in 
the study should be considered as exploratory and hypothesis-generating. 
Selection bias is possible because one third of the patients registered at the clinic 
refused to participate. Patients who declined may have had a better or worse health 
status compared to the participants, leading to either over- or underestimation of 
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physical problems. Age and gender of the non-participants did not differ from the 
participants, suggesting that at least these variables did not bias the results. Self-
reporting may cause recall bias. Moreover, persons with SMI may have an excess of 
difficulties in reporting due to cognitive impairment, lack of insight and current 
psychotic symptoms. In addition, no data exists on the duration of the psychotic 
illness or previous medications of the participants.  
Self-formulated classifications for constipation and dyspepsia (III), and for 
interventions by type of disease (I) can be seen as limitations because the results are 
difficult to compare with studies based on diagnoses derived from registers or 
databases. Standardized classifications, e.g. the Rome definitions for gastrointestinal 
symptoms, tend to be too complex and time consuming to use in clinical practice, let 
alone among patients with cognitive difficulties. According to the American College 
of Gastroenterology, chronic idiopathic constipation is defined as  “a symptom-
based disorder defined as unsatisfactory defecation and characterized by infrequent 
stools, difficult stool passage, or both”  (Ford et al., 2014).  Whereas according to 
Ford and Moayyedi, dyspepsia can be defined in primary care as “epigastric pain or 
discomfort for at least three months, in a patient who does not report predominant 
heartburn or regurgitation (although these symptoms can be part of the overall 
symptom complex)” (Ford and Moayyedi, 2013). The broad definitions used to 
define gastrointestinal problems and need for interventions in this study may hinder 
the external validity, but on the other hand, arguably decrease the number of false 
negatives. 
Considering the consequences of cerumen impaction for the participants, in the 
absence of an audiometry, the evaluation of potentially impaired hearing is difficult. 
In Study IV only one patient out of 12 with cerumen impaction complained of 
symptoms: loss of hearing and dizziness. 
Having a single GP, although experienced, executing all health examinations 
may have caused bias due to the subjectiveness of the evaluations. On the other 
hand, the study setting made it possible to have abundant time and comprehensive 
background information for the patients. The resources are usually more limited in 
clinical practice. Regarding the generalizability of the results, this can be seen either 
as a strength or a limitation.  
The results of the current study can be generalized to countries with healthcare 
systems similar to Finland, where the community healthcare is financially accessible 
to the citizens because it is almost entirely financed by the municipalities. 
Appointments at psychosis outpatient clinics and laboratory tests are free of charge, 
and appointments in the health centre are rather affordable (approximately 20 euros 
for GP visit, 30-70 euros for a dentist, 10 euros for a visit to a registered nurse or to a 
physiotherapist). 
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7 CONCLUSIONS AND FUTURE RESEARCH 
This thesis, based on the “Living Conditions and the Physical Health of Outpatients 
with Schizophrenia” Study, assessed overall physical healthcare needs and three 
specific somatic health problems (MetS, gastrointestinal symptoms, cerumen 
impaction) among patients with schizophrenia. In the study a GP conducted a 
structured, comprehensive health examination in 275 patients from the psychosis 
outpatient clinic of Kellokoski Hospital between 2009 and 2013.  
 
- Of the participants with a mean age of 45 years (SD 12.6), 85% were centrally 
obese. The mean BMI in the sample was 30.2 (SD 6.7). Almost half of the 
participants (41%) were sedentary and 38% were current smokers.  
 
- Nearly one half of the participants (45%) reported distressing somatic symptoms, 
most commonly musculoskeletal, gastrointestinal and neurological complaints. Of 
the participants, 88% needed interventions for a disease or condition. The variety of 
the recommended interventions was large. The risk associated with a need for any 
type of intervention was more than doubled among current smokers and obese 
participants. Lifestyle counselling, most often regarding obesity, sedentariness and 
smoking was given to 81% of the participants. 
 
- The prevalence of MetS was high (59%). Clozapine use doubled the risk of MetS, 
whereas self-reported physical activity decreased the risk.  
 
- Gastrointestinal problems were common, one out of three had constipation and one 
out of four dyspepsia. Participants using clozapine had over a 5-fold risk for 
constipation. In addition, paracetamol use and living in sheltered housing were 
associated with an increased risk for constipation. Risk for dyspepsia was doubled 
among women, users of NSAIDs and users of diabetes medication.  
 
- A high prevalence of cerumen impaction was shown for the first time among 
patients with schizophrenia. Living in sheltered housing was associated with higher 
odds of having cerumen impaction.  
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Albeit challenging to execute, the effectiveness of health examinations and somatic 
interventions on physical health in patients with schizophrenia should be evaluated 
in RCTs. Due to the ongoing shortage of GPs and psychiatrists, at least in Finnish 
healthcare (Rellman, 2016), the role of registered nurses and case managers in 
conducting health examinations is important to assess. In addition, feasibility and 
impact of long-term prevention and treatment studies on weight monitoring, and 
smoke-free and less obesogenic psychiatric settings are warranted.  
The impact of removal of cerumen impaction on hearing, cognition and social 
interaction in patients with schizophrenia deserves to be studied further. In addition, 
common dermatological problems (mainly eczema) deserve more focus in research 
and in the treatment. Plausible somatic concerns of aging individuals with 
schizophrenia (e.g. mobility difficulties, loss of hearing) ought to be addressed more 
in future research. 
Possible effects of drug-induced constipation to gut microbiome and physical 
health, especially in patients using clozapine, may be worth investigating. 
Prevalence, correlates, prevention and management of non-alcoholic fatty liver 
disease are important issues to focus on in the research of somatic comorbidity in 
SMI.  
Schizophrenia patients’ perceptions of the impact of somatic symptoms on 
psychiatric treatment adherence and their own preferences concerning prevention 
and treatment of somatic adversities should be evaluated. 
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8 CLINICAL IMPLICATIONS 
8.1.1 HEALTH EXAMINATIONS 
The wide range and amount of physical problems among outpatients with 
schizophrenia shown in the present study indicate that somatic health examinations 
in this patient group are necessary. A suggestion for the contents of a health 
examination is presented in Table 21. 
Table 21. An outline of the somatic health examination for a person with schizophrenia. 
 
 
Method 
Lifestyle, self-care  Questionnaire1 (questions concerning, e.g. physical activity, 
Heaviness of Smoking Index, AUDIT-C, tooth brushing, GP and 
dentist visits). For smokers, an additional questionnaire with 
instructions for nicotine replacement therapy2  
Medication use 
 
Interview, Electronic prescription database 
Antipschotic 
medication side effects  
Questionnaires: SMARTS3, GASS-C4 for clozapine users  
Measurements5 Height, Weight, Body Mass Index, Waist circumference, Blood 
pressure, Pulse rate 
Laboratory tests5 Total blood count, Sodium, Potassium, Ionized calcium, Creatinine, 
Fasting glucose, Glycated haemoglobin, Total and High and Low 
density cholesterol, Triglycerides, Alanine aminotransferase, 
Thyroid-stimulating hormone, 25-Hydroxyvitamin D, 
Electrocardiogram 
Anamnesis 
 
Somatic complaints, symptoms of constipation 
Physical examination Basic examination of the mouth, Otoscopy, Evaluation of the skin, 
Auscultation of lungs and heart, Palpation of abdomen, Near and 
distant vision, Audiometry (elderly patients) 
Preventive measures Questionnaire or Interview: Annual influenza vaccination, 
Participation in screening mammography and Pap test, Weighing 
scale at home 
Motivation for lifestyle 
change  
Questionnaire, Interview 
Need of additional 
support in self-care  
Information gathered from the patient, his/her caregiver and the 
case manager/nurse 
1(Health Hut, 2015a) 
2(Health Hut, 2015b) 
3 SMARTS (Haddad et al., 2014) 
4 GASS-C (Hynes et al., 2015) 
5 In FE psychosis assessment of weight, lipids and blood glucose according to guidelines and 
special instructions for monitoring concerning certain medications (e.g. sertindole, lithium)  
Clinical implications 
88 
According to the authors´s impression, the participants of the current study were 
interested in communicating their physical health issues and, in most cases, highly 
receptive to the interventions given by the GP. However, structured feedback from 
the participants on the health examination was not gathered.  
In the health examination the participants of the current study were typically 
exposed to several suggestions regarding lifestyle modifications. Suggestions of 
lifestyle modification were executed mainly by using the principles of motivational 
interviewing, making the communication more acceptable. Motivational 
interviewing as a technique has been shown to be relatively effective in e.g. treating 
alcohol use disorders among outpatients with schizophrenia (De Witte et al., 2014). 
Although there was an abundant amount of time in the appointment (compared to 
routine clinical conditions), the considerable amount of information delivered to the 
patient made it usually impossible to conduct a comprehensive motivational 
interview.  
8.1.2 PROMOTION OF HEALTHY LIFESTYLE 
The high risk for MetS, T2D and obesity in schizophrenia, mainly attributable to 
adverse lifestyle and AP medications, emphasizes the importance of healthy lifestyle 
promotion from the beginning of the psychiatric illness. Healthy lifestyle issues 
should be endorsed across psychiatric services (in- and outpatient settings, sheltered 
housing), in both system and individual levels (Ward et al., 2015b).  
FEP interventions focused on healthy diet and physical activity have shown to be 
feasible and efficient (Curtis et al., 2016,Teasdale et al., 2016). In addition, losing 
weight and engaging in physical activity is the gold standard of T2D prevention 
(Tuomilehto et al., 2001). Furthermore, regular self-weighing has shown to be an 
effective method in losing weight and preventing weight gain (and causing no 
psychological harm) in individuals seeking help for being overweight or obesity 
(Zheng et al., 2015b). Although no studies exist of T2D prevention in schizophrenia, 
it is reasonable to assume that lifestyle modifications would also have an impact in 
this patient group. 
Individuals using AP medications should receive understandable information, 
appropriate assessment of the possible metabolic disturbances and efficient 
interventions to counteract or cure them. Moreover, patients could benefit from a 
checklist to help them follow their personal somatic care and monitore it more 
actively. In addition, the personnel may benefit from straightforward algorithms of 
the needed interventions Shiers et al., 2014). The Healthy Active Lives declaration 
can be used as education material for patients, families and personnel in raising 
awareness of somatic health issues (International Physical Health in Youth (iphYs) 
working group, 2016).  
 In addition to actively offering support for smoking cessation, providing smoke-
free environments is essential in protecting both SMI patients and psychiatric staff 
from passive exposure to tobacco smoke (Ruther et al., 2014). In several countries 
(e.g. UK, USA, Australia) smoking bans have been launched in psychiatric hospitals 
over the last decade. Clear leadership, staff education, teamwork, low staff smoking 
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rates and an option of combination nicotine replacement therapy have been shown as 
key elements associated with a successful changeover to a smoke-free facility (Lawn 
and Campion, 2010). Reassurringly, the implementation of a smoke-free policy in 
psychiatric facilities has been shown to be achieveable despite the traditional culture 
of acceptance of smoking and cigarettes considered as patient management tools 
(Lawn and Campion, 2013). In addition, despite the feared consequence of a 
smoking ban, there is no evidence that the implementation of smoke-free wards 
having resulted in increased aggression and agitation among inpatients (Lawn and 
Campion, 2013). Rather, staff members with a history of smoking cessation may 
offer peer support to patients considering quitting, or vice versa. 
The integrated care of alcohol and substance problems in patients with 
schizophrenia is important, and should also take physical comorbidities related to 
substance use into account. 
8.1.3 THE HEALTH HUT 
Based on the experience gained from the current study, the author has been 
developing services for the somatic care of schizophrenia patients in the Helsinki 
and Uusimaa Hospital District. In January 2015, a service called the Health Hut was 
founded in Kellokoski Hospital and Hyvinkää Hospital Area Psychosis outpatient 
clinic in order to integrate elements of somatic care into psychiatric services. The 
Medical Center in UPC KU Leuven campus Kortenberg in Belgium has served as an 
inspiration to the Hut (De Hert et al., 2010). 
The Health Hut is best described as a network of professionals working in a 
psychiatric setting and sharing an interest in physical health. The network contains a 
GP (the author), nurse-agents, instructors, physical activity and nutrition 
professionals and a dentist. The aim is to promote better physical health for the 
patients in psychiatric services by introducing and implementing new system level 
procedures. Table 22 shows interventions of somatic care that have been 
accomplished so far. The author has presented the model in several meetings and 
seminars, and is engaged in working groups on the topic. In the future, the Health 
Hut model will be disseminated within the hospital district and nationally by existing 
and upcoming digital platforms (MentalHub). 
A multidisciplinary, innovative network focusing on somatic health appears to be 
an efficient model in developing interventions into daily practice in psychiatric 
settings.  
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Table 22. Interventions of the Health Hut to overcome somatic problems in the treatment of 
patients with schizophrenia. 
Problem Intervention 
 
Lack of somatic expertise in psychiatric setting General practitioner working in a psychiatric 
facility, training of the staff 
Lack of multidisciplinary collaboration in 
somatic issues 
Health Hut Team, collaboration with other 
specialities and national organizations  
Difficulties in implementing new processes, 
lack of knowledge in the administrative level of 
the grass-roots problems  
Hut Agents in the hospital wards and 
outpatient care 
High rates of smoking Anti-smoking Team 
 
Epidemic of obesity Anti-obesity Working Group 
 
Lack of systematic somatic assessment and 
lifestyle support for first-episode patients  
Promoting Health Positively  
 
Increased risk of influenza and other infections Pop-up Vaccination Day in the outpatient 
clinic, enhancing vaccination coverage in the 
hospital wards (both staff and patients), 
promoting hand disinfection 
Outdated first-aid equipment and lack of 
emergency skills  
First-aid Update 
Costly self-monitoring equipment and patients’ 
lack of skills to use them 
Hut Corner in the outpatient clinic with blood 
pressure monitor and instructions, weighing 
scale and stadiometer  
Lack of knowledge of clozapine side effects 
and how to react in case of fever 
A leaflet of instructions in plain language for 
patients, caregivers and primary care 
providers 
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